US20080125375A1 - Protease inhibitors - Google Patents
Protease inhibitors Download PDFInfo
- Publication number
- US20080125375A1 US20080125375A1 US11/949,364 US94936407A US2008125375A1 US 20080125375 A1 US20080125375 A1 US 20080125375A1 US 94936407 A US94936407 A US 94936407A US 2008125375 A1 US2008125375 A1 US 2008125375A1
- Authority
- US
- United States
- Prior art keywords
- compound
- heterocycloalkyl
- alkyl
- aryl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title abstract 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 249
- 241000700605 Viruses Species 0.000 claims abstract description 17
- 208000015181 infectious disease Diseases 0.000 claims abstract description 17
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 claims description 123
- 125000003118 aryl group Chemical group 0.000 claims description 103
- 125000001072 heteroaryl group Chemical group 0.000 claims description 87
- 125000004429 atom Chemical group 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 54
- 108091005804 Peptidases Proteins 0.000 claims description 35
- 239000004365 Protease Substances 0.000 claims description 35
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 33
- 229910052736 halogen Inorganic materials 0.000 claims description 30
- 150000002367 halogens Chemical class 0.000 claims description 26
- 230000003612 virological effect Effects 0.000 claims description 16
- 241000711573 Coronaviridae Species 0.000 claims description 12
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 208000005176 Hepatitis C Diseases 0.000 claims description 7
- 241000711549 Hepacivirus C Species 0.000 claims description 6
- 241000315672 SARS coronavirus Species 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 241000711467 Human coronavirus 229E Species 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 224
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 153
- 238000002360 preparation method Methods 0.000 description 147
- 238000005160 1H NMR spectroscopy Methods 0.000 description 121
- 239000000243 solution Substances 0.000 description 43
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 41
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 32
- 239000000203 mixture Substances 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- 239000012044 organic layer Substances 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Inorganic materials O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 12
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- -1 —CH2— Chemical group 0.000 description 11
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 229910001415 sodium ion Inorganic materials 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 0 *C(*)(*C(C(*)(*)N*)=O)C(NC(*)(*)C(*)=C(*)*)=O Chemical compound *C(*)(*C(C(*)(*)N*)=O)C(NC(*)(*)C(*)=C(*)*)=O 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- SMMDSQSUKNRPFZ-UHFFFAOYSA-N CC(C)(C)CC1CCCC1=O Chemical compound CC(C)(C)CC1CCCC1=O SMMDSQSUKNRPFZ-UHFFFAOYSA-N 0.000 description 7
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000003862 amino acid derivatives Chemical class 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 238000010189 synthetic method Methods 0.000 description 5
- 239000012267 brine Substances 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 4
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 3
- SRKGZXIJDGWVAI-GVAVTCRGSA-M (e,3r)-7-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)C1=NC(C(C)(C)C)=CC(C=2C=CC(F)=CC=2)=C1\C=C\C(O)C[C@@H](O)CC([O-])=O SRKGZXIJDGWVAI-GVAVTCRGSA-M 0.000 description 3
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 3
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940125900 compound 59 Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 3
- 229960002989 glutamic acid Drugs 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000004665 trialkylsilyl group Chemical group 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 2
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 2
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 2
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 2
- OIIOPWHTJZYKIL-PMACEKPBSA-N (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one Chemical compound C1(=C(N=C(C2=C(C(C3=CC=CC(=C3Cl)C3=NC(OC)=C(N=C3)CNC[C@H]3NC(=O)CC3)=CC=C2)Cl)C=N1)OC)CNC[C@H]1NC(=O)CC1 OIIOPWHTJZYKIL-PMACEKPBSA-N 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 2
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 2
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 2
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 2
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 2
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 2
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 2
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 2
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 2
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 2
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 2
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 2
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 2
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 2
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 description 2
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 2
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 2
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 2
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 2
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 2
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 2
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 2
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 2
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 2
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 241001144416 Picornavirales Species 0.000 description 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
- 108700022715 Viral Proteases Proteins 0.000 description 2
- 238000007239 Wittig reaction Methods 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 229940126540 compound 41 Drugs 0.000 description 2
- 229940125936 compound 42 Drugs 0.000 description 2
- 229940125844 compound 46 Drugs 0.000 description 2
- 229940127271 compound 49 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 229940126545 compound 53 Drugs 0.000 description 2
- 229940127113 compound 57 Drugs 0.000 description 2
- 229940126179 compound 72 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- ZBELDPMWYXDLNY-UHFFFAOYSA-N methyl 9-(4-bromo-2-fluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Br)C=C1F ZBELDPMWYXDLNY-UHFFFAOYSA-N 0.000 description 2
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 2
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 2
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- QYYZXEPEVBXNNA-QGZVFWFLSA-N (1R)-2-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound C(C)(=O)N1[C@H](C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)O QYYZXEPEVBXNNA-QGZVFWFLSA-N 0.000 description 1
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- FHUDAMLDXFJHJE-UHFFFAOYSA-N 1,1,1-trifluoropropan-2-one Chemical compound CC(=O)C(F)(F)F FHUDAMLDXFJHJE-UHFFFAOYSA-N 0.000 description 1
- LTDMAZYOZAESKX-UHFFFAOYSA-N 1-(1,1,1-trifluoropropan-2-ylidene)pyrrolidin-1-ium Chemical compound FC(F)(F)C(C)=[N+]1CCCC1 LTDMAZYOZAESKX-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- VRJWCYOICIRDSE-UHFFFAOYSA-N 1-o-tert-butyl 1-o,3-o-dimethyl 1-amino-4-cyanobutane-1,1,3-tricarboxylate Chemical compound COC(=O)C(CC#N)CC(N)(C(=O)OC)C(=O)OC(C)(C)C VRJWCYOICIRDSE-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FBPINGSGHKXIQA-UHFFFAOYSA-N 2-amino-3-(2-carboxyethylsulfanyl)propanoic acid Chemical compound OC(=O)C(N)CSCCC(O)=O FBPINGSGHKXIQA-UHFFFAOYSA-N 0.000 description 1
- AFAYEVXDPHDLGM-UHFFFAOYSA-N 2-amino-3-[(2-methylpropan-2-yl)oxy]-2-phenylmethoxycarbonylbutanoic acid Chemical compound CC(C)(C)OC(C)C(N)(C(O)=O)C(=O)OCC1=CC=CC=C1 AFAYEVXDPHDLGM-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- JUKRJGQYUNADDD-UHFFFAOYSA-N Br.O=C1OCC[C-]1[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound Br.O=C1OCC[C-]1[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 JUKRJGQYUNADDD-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- XPFCVCGOOLULSB-FDXCNXHGSA-N C/C=C(/C)C(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.C=C(C)C(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.C=CC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)C)C(C)OC(C)(C)C.CC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C(=O)C1CC1)C[C@@H]1CCNC1=O Chemical compound C/C=C(/C)C(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.C=C(C)C(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.C=CC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)C)C(C)OC(C)(C)C.CC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C(=O)C1CC1)C[C@@H]1CCNC1=O XPFCVCGOOLULSB-FDXCNXHGSA-N 0.000 description 1
- GFIAKOPVZFMTLW-HKGQMBDCSA-N C/C=C(\C)C(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.C=CC(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CC(=O)N1CC/C(=C\[C@H](C[C@@H]2CCNC2=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC2=CC=CC=C2)C(C)OC(C)(C)C)C1=O.CC(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(=O)C(C)(C)C)C(=O)N[C@H](/C=C/C#N)CC1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(=O)C(C)(C)C)C(=O)N[C@H](/C=C1\CCCC1=O)C[C@@H]1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C1\CCOC1=O)C[C@@H]1CCNC1=O.COC(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.[H]C(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C Chemical compound C/C=C(\C)C(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.C=CC(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CC(=O)N1CC/C(=C\[C@H](C[C@@H]2CCNC2=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC2=CC=CC=C2)C(C)OC(C)(C)C)C1=O.CC(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(=O)C(C)(C)C)C(=O)N[C@H](/C=C/C#N)CC1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(=O)C(C)(C)C)C(=O)N[C@H](/C=C1\CCCC1=O)C[C@@H]1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C1\CCOC1=O)C[C@@H]1CCNC1=O.COC(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.[H]C(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C GFIAKOPVZFMTLW-HKGQMBDCSA-N 0.000 description 1
- SKFQJBIYFTZTAO-OUMQGPNCSA-N C=CCOC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CC(C)COC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C(=O)OC1CCCC1)CC1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C1\CCOC1=O)C[C@@H]1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](CO)C[C@@H]1CCNC1=O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CN(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.COC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CON(C)C(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C Chemical compound C=CCOC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CC(C)COC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C(=O)OC1CCCC1)CC1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C1\CCOC1=O)C[C@@H]1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](CO)C[C@@H]1CCNC1=O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CN(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.COC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CON(C)C(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C SKFQJBIYFTZTAO-OUMQGPNCSA-N 0.000 description 1
- LZBQNJMNMNPXBA-AOQKDYLMSA-N C=CCOC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](/C=C/C(=O)OCC)C[C@@H]1CCNC1=O)C(C)OC(C)(C)C.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C#N)CC1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C(=O)O)CC1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C(=O)OC(C)C)CC1CCNC1=O.CCOC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC(C)C)N1CCCCC(NC(=O)OC(C)(C)C)C1=O.CCOC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC(C)C)N1CCCCC(NC(=O)OCC2=CC=CC=C2)C1=O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(=O)C(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NS(=O)(=O)CC1=CC=CC=C1)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1 Chemical compound C=CCOC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](/C=C/C(=O)OCC)C[C@@H]1CCNC1=O)C(C)OC(C)(C)C.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C#N)CC1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C(=O)O)CC1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C(=O)OC(C)C)CC1CCNC1=O.CCOC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC(C)C)N1CCCCC(NC(=O)OC(C)(C)C)C1=O.CCOC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC(C)C)N1CCCCC(NC(=O)OCC2=CC=CC=C2)C1=O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(=O)C(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NS(=O)(=O)CC1=CC=CC=C1)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1 LZBQNJMNMNPXBA-AOQKDYLMSA-N 0.000 description 1
- QLCVJXNVKXOOCR-NSCUHMNNSA-N CC(=O)/C=C/C(CC1CCNC1=O)NP Chemical compound CC(=O)/C=C/C(CC1CCNC1=O)NP QLCVJXNVKXOOCR-NSCUHMNNSA-N 0.000 description 1
- XCPVTDJALUCMKE-ZSTIQDAESA-N CC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)C(=O)OC(C)(C)C.CC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1.CC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CNC(=O)C(C)(C)C)NC(=O)OCC1=CC=CC=C1.CC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CNC(=O)C1CCCCC1)NC(=O)OCC1=CC=CC=C1.CC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CNC(=O)CC(C)(C)C)NC(=O)OCC1=CC=CC=C1.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)C(=O)OC(C)(C)C)C(=O)N[C@H](/C=C1\CCOC1=O)C[C@@H]1CCNC1=O.CC(C)C[C@H](NC(=O)[C@H](CNC(=O)C(C)(C)C)NC(=O)OCC1=CC=CC=C1)C(=O)N[C@H](/C=C1\CCOC1=O)C[C@@H]1CCNC1=O.CC(C)C[C@H](NC(=O)[C@H](CNC(=O)NC(C)(C)C)NC(=O)OCC1=CC=CC=C1)C(=O)N[C@H](/C=C1\CCOC1=O)C[C@@H]1CCNC1=O.CCC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CON(C)C(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CNC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1 Chemical compound CC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)C(=O)OC(C)(C)C.CC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1.CC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CNC(=O)C(C)(C)C)NC(=O)OCC1=CC=CC=C1.CC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CNC(=O)C1CCCCC1)NC(=O)OCC1=CC=CC=C1.CC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CNC(=O)CC(C)(C)C)NC(=O)OCC1=CC=CC=C1.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)C(=O)OC(C)(C)C)C(=O)N[C@H](/C=C1\CCOC1=O)C[C@@H]1CCNC1=O.CC(C)C[C@H](NC(=O)[C@H](CNC(=O)C(C)(C)C)NC(=O)OCC1=CC=CC=C1)C(=O)N[C@H](/C=C1\CCOC1=O)C[C@@H]1CCNC1=O.CC(C)C[C@H](NC(=O)[C@H](CNC(=O)NC(C)(C)C)NC(=O)OCC1=CC=CC=C1)C(=O)N[C@H](/C=C1\CCOC1=O)C[C@@H]1CCNC1=O.CCC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CON(C)C(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CNC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1 XCPVTDJALUCMKE-ZSTIQDAESA-N 0.000 description 1
- HHVHCQHWBZLDNM-RXJHMKSJSA-N CC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC1CCCCC1.CC(OC(C)(C)C)[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](/C=C/C(=O)C1CC1)CC1CCNC1=O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C Chemical compound CC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC1CCCCC1.CC(OC(C)(C)C)[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](/C=C/C(=O)C1CC1)CC1CCNC1=O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C HHVHCQHWBZLDNM-RXJHMKSJSA-N 0.000 description 1
- DFIAFAXYCZDSAT-MLJDXZEOSA-N CC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CNC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(=O)NC(C)(C)C)C(=O)N[C@H](CCl)C[C@@H]1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C(=O)C(C)C)C[C@@H]1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C(=O)C(F)(F)F)C[C@@H]1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](CCl)C[C@@H]1CCNC1=O.[H]C(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(=O)NC(C)(C)C.[H]C(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1.[H]C(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C Chemical compound CC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CNC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(=O)NC(C)(C)C)C(=O)N[C@H](CCl)C[C@@H]1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C(=O)C(C)C)C[C@@H]1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C(=O)C(F)(F)F)C[C@@H]1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](CCl)C[C@@H]1CCNC1=O.[H]C(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(=O)NC(C)(C)C.[H]C(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1.[H]C(=O)[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C DFIAFAXYCZDSAT-MLJDXZEOSA-N 0.000 description 1
- OPQMOZFFSCBICU-ZFLFOEFOSA-N CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C(=O)NC(C)C)CC1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C(=O)OC(C)C1=CC=CC=C1)CC1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C(=O)OCC1=CC=CC=C1)CC1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C(=O)OCC1CC1)CC1CCNC1=O.CON(C)C(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C(=O)NC(C)C)CC1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C(=O)OC(C)C1=CC=CC=C1)CC1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C(=O)OCC1=CC=CC=C1)CC1CCNC1=O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C)C(=O)N[C@H](/C=C/C(=O)OCC1CC1)CC1CCNC1=O.CON(C)C(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C OPQMOZFFSCBICU-ZFLFOEFOSA-N 0.000 description 1
- HAUYMDFKOIUMJZ-KVYLFAHDSA-N CCNC(=S)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](/C=C/C(=O)OCC)C[C@@H]1CCNC1=O)C(C)O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CCC1=CC=CC=C1)C(C)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC)C(C)O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=O)OC)NC(=O)OC.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNS(C)(=O)=O)NS(C)(=O)=O Chemical compound CCNC(=S)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](/C=C/C(=O)OCC)C[C@@H]1CCNC1=O)C(C)O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CCC1=CC=CC=C1)C(C)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC)C(C)O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=O)OC)NC(=O)OC.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNS(C)(=O)=O)NS(C)(=O)=O HAUYMDFKOIUMJZ-KVYLFAHDSA-N 0.000 description 1
- XTHAIUNZHRFRGS-JESUVPKGSA-N CCOC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)O.CCOC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCNC(=O)OC)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)N1CCC(N)C1=O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)N1CCC(NC(=O)OC(C)(C)C)C1=O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)N1CCC(NC(=O)OCC2=CC=CC=C2)C1=O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OC)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCCCl)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(C)=O)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NS(=O)(=O)C(F)(F)F)C(C)OC(C)(C)C Chemical compound CCOC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)O.CCOC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCNC(=O)OC)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)N1CCC(N)C1=O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)N1CCC(NC(=O)OC(C)(C)C)C1=O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)N1CCC(NC(=O)OCC2=CC=CC=C2)C1=O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OC)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCCCl)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(C)=O)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NS(=O)(=O)C(F)(F)F)C(C)OC(C)(C)C XTHAIUNZHRFRGS-JESUVPKGSA-N 0.000 description 1
- AIQIUFYKVHBLKF-JONMSFOXSA-N CCOC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)C(CCCCN)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC1=CC=C(F)C=C1)NC(=O)[C@@H](NC(=O)C1=NOC(C)=C1)C(C)O.CCOC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)C1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)C1=CC=CO1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)C1=NOC(C)=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)NC(=O)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=O)OC(C)(C)C)NC(=O)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CNC(=O)OC(C)(C)C)NC(=O)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)C1=CC=CC=C1)C(C)C Chemical compound CCOC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)C(CCCCN)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CC1=CC=C(F)C=C1)NC(=O)[C@@H](NC(=O)C1=NOC(C)=C1)C(C)O.CCOC(=O)/C=C/[C@H](CC1CCNC1=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)C1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)C1=CC=CO1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)C1=NOC(C)=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)NC(=O)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=O)OC(C)(C)C)NC(=O)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CNC(=O)OC(C)(C)C)NC(=O)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)C1=CC=CC=C1)C(C)C AIQIUFYKVHBLKF-JONMSFOXSA-N 0.000 description 1
- YFTPYCROXOJQMF-IDZYPJJOSA-N CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)NCCCl)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NS(=O)(=O)CC)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NS(C)(=O)=O)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NS(C)(=O)=O)C(C)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NS(C)(=O)=O)C(C)OS(C)(=O)=O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](COC)NC(=O)[C@H](CO)NC(=O)OCC1=CC=CC=C1 Chemical compound CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)NCCCl)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NS(=O)(=O)CC)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NS(C)(=O)=O)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NS(C)(=O)=O)C(C)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NS(C)(=O)=O)C(C)OS(C)(=O)=O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](COC)NC(=O)[C@H](CO)NC(=O)OCC1=CC=CC=C1 YFTPYCROXOJQMF-IDZYPJJOSA-N 0.000 description 1
- YLBLIVNKEMFDOW-HXVLLWQTSA-N CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)NC1=CC=CC=C1)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)NCC(=O)OCC)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)NCCCl)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCCOCC1=CC=CC=C1)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)C1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CNC(=O)OC)NC(=O)OC Chemical compound CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)NC1=CC=CC=C1)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)NCC(=O)OCC)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)NCCCl)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCCOCC1=CC=CC=C1)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)C1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CNC(=O)OC)NC(=O)OC YLBLIVNKEMFDOW-HXVLLWQTSA-N 0.000 description 1
- VAIBVIWHHFMSSL-QKFUJKOKSA-N CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OC(C)C)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCCCl)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCNC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCNC(=O)OC)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCNS(C)(=O)=O)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=O)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCS(C)(=O)=O)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CNC[C@H](C)O)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)OC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C Chemical compound CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OC(C)C)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCCCl)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCNC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCNC(=O)OC)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCNS(C)(=O)=O)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=O)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCS(C)(=O)=O)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CNC[C@H](C)O)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)OC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C VAIBVIWHHFMSSL-QKFUJKOKSA-N 0.000 description 1
- XWYLDSLTFOVKMS-DSUBKBKBSA-N CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)OC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CCCCN)NC(=O)OCC1=CC=CC=C1 Chemical compound CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)OC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CCCCN)NC(=O)OCC1=CC=CC=C1 XWYLDSLTFOVKMS-DSUBKBKBSA-N 0.000 description 1
- SLXINMHHDVTAFC-MHEICJLUSA-N CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)OCC1=CN=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](COC(C)(C)C)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](COS(C)(=O)=O)NC(=O)OCC1=CC=CC=C1 Chemical compound CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)O.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OC(C)(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)OCC1=CN=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](COC(C)(C)C)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](COS(C)(=O)=O)NC(=O)OCC1=CC=CC=C1 SLXINMHHDVTAFC-MHEICJLUSA-N 0.000 description 1
- NHHFJMOBIGZEFG-AGZSRRAYSA-N CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC(F)=C(F)C=C1)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(F)C=C1)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CN(C(=O)OC(C)(C)C)C=N1)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC=N1)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1 Chemical compound CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC(F)=C(F)C=C1)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(F)C=C1)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CN(C(=O)OC(C)(C)C)C=N1)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC=N1)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)OCC1=CC=CC=C1)C(C)C.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1.CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CC=CC=C1 NHHFJMOBIGZEFG-AGZSRRAYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- CVPGAJURWPTFCB-UHFFFAOYSA-N O=C1CCCC1=P(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound O=C1CCCC1=P(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 CVPGAJURWPTFCB-UHFFFAOYSA-N 0.000 description 1
- IILDKVZTMZDZSC-UHFFFAOYSA-N O=C1NCCC1CC(NP)C(=O)OPP Chemical compound O=C1NCCC1CC(NP)C(=O)OPP IILDKVZTMZDZSC-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000006859 Swern oxidation reaction Methods 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 125000004986 diarylamino group Chemical group 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- QNSPKWUAZQIIGZ-QMMMGPOBSA-N dimethyl (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanedioate Chemical compound COC(=O)CC[C@@H](C(=O)OC)NC(=O)OC(C)(C)C QNSPKWUAZQIIGZ-QMMMGPOBSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- FLAJQFOSRMJUDQ-UHFFFAOYSA-N ethyl 4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-(2-oxopyrrolidin-3-yl)pent-2-enoate Chemical compound CCOC(=O)C=CC(NC(=O)OC(C)(C)C)CC1CCNC1=O FLAJQFOSRMJUDQ-UHFFFAOYSA-N 0.000 description 1
- ABKFVTIRQAVGDW-UHFFFAOYSA-N ethyl 4-[[4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]amino]-5-(2-oxopyrrolidin-3-yl)pent-2-enoate Chemical compound CC(C)(C)OC(=O)NC(CC(C)C)C(=O)NC(C=CC(=O)OCC)CC1CCNC1=O ABKFVTIRQAVGDW-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- FGYXQBPXHQHYNU-UHFFFAOYSA-M magnesium;but-2-ene;bromide Chemical compound [Mg+2].[Br-].CC=[C-]C FGYXQBPXHQHYNU-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- IASISKBRBNTMFU-UHFFFAOYSA-N tert-butyl n-[1-hydroxy-3-(2-oxopyrrolidin-3-yl)propan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC(CO)CC1CCNC1=O IASISKBRBNTMFU-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Description
- This application is a divisional application of U.S. Utility Application Ser. No. 11/024,929, filed on Dec. 29, 2004, which in turn claims priority to U.S. Provisional Application Ser. No. 60/533,779, filed Dec. 31, 2003. The contents of both applications are hereby incorporated by reference.
- Coronavirus is a family of viruses that have the appearance of a corona when viewed under a microscope. Members of the coronavirus family can cause hepatitis in mice, gastroenteritis in pigs, and respiratory infections in birds and humans. Coronavirus was first isolated from chickens in 1937 by Beaudette and Hudson. In 1965, Tyrrell and Bynoe used cultures of human ciliated embryonic trachea to propagate the first human coronavirus in vitro.
- Among the more than 30 strains of coronavirus isolated so far, three or four infect humans. For example, the severe acute respiratory syndrome, a newly emerged infectious disease, is associated with a novel coronavirus (Ksiazek et al. New England Journal Medicine, 2003, 348(20): 1953-1966). This life-threatening respiratory disease caused worldwide outbreaks in 2003. Vaccines and drugs against severe acute respiratory syndrome virus are being vigorously sought. Nevertheless, the progress is rather slow due to safety concerns. Thus, there exists a need to develop drags that are effective in treating infections with corona viruses, as well as infections with other viruses.
- This invention is based on the unexpected discovery that certain peptide-like compounds are effective in treating viral infections by inhibiting viral proteases (e.g., corona viral 3CL proteases, picornaviral proteases, or hepatitis C viral proteases).
- In one aspect, this invention features a method for treating an infection with a virus. The method includes administering to a subject in need thereof an effective amount of a compound of formula (I):
- In this formula, X is N(Ra1), O, or CH2; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; in which Ra1 is H or C1-C15 alkyl; R1 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, C(O)Rb1, CO2Rb1, C(O)NRb1Rb2, C(O)—N(Rb1)—ORb2, C(S)Rb1, C(S)NRb1Rb2, S(O)Rb1, SO2Rb1, S(O)NRb1Rb2, S(O)—N(Rb1)—ORb2, SO2NRb1Rb2, or SO3Rb1; in which each of Rb1 and Rb2, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl; each of R2 and R3, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, ORc1, SRc1, or NRc1Rc2; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; in which each of Rc1 and Rc2, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl; each of R4 and R5, independently, is H, halogen, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl; one of R6 and R7 is C1-C15 alkyl substituted with C3-C20 heterocycloalkyl, heteroaryl, or aryl; and the other of R6 and R7 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl; R8 is H, halogen, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, ORd1, or SRd1; in which Rd1 is H and C1-C15 alkyl; and each of R9 and R10, independently, is H, halogen, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, C(O)Re1, CO2Re1, C(O)NRe1Re2, C(O)—N(Re1)—ORe2, C(S)Re1, C(S)NRe1Re2, CN, NO2, S(O)Re1, SO2Re1, S(O)NRe1Re2, S(O)—N(Re1)—ORe2, SO2NRe1Re2, SO3Re1, PO(ORe1)(ORe2), PO(Re1)(Re2), PO(NRe1Re2)(ORe3), PO(NRe1Re2)(NRe3Re4), C(O)—N(Re1)—NRe2Re3 or C(S)—N(Re1)—NRe2Re3; or R8 and R10, taken together, is C3-C20 cycloalkyl or C3-C20 heterocycloalkyl; or R9 and R10, taken together, is C3-C20 cycloalkyl or C3-C20 heterocycloalkyl; in which each of Re1, Re2, Re3, and Re4, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl C3-C20 heterocycloalkyl, heteroaryl, or aryl; or any two of Re1, Re2, Re3, and Re4, together with the atom or atoms to which they are bonded, is C3-C20 heterocycloalkyl; and the virus is a coronavirus or a hepatitis C virus.
- In particular, this invention features a method for treating an infection with a severe acute respiratory syndrome virus, a human coronavirus 229E, or a hepatitis C virus, by administering to a subject in need thereof an effective amount of a compound of formula (I) shown above.
- For example, one can administer to a subject infected with a virus (e.g., a severe acute respiratory syndrome virus) a compound of formula (I), in which X is N(Ra1) or O; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; R1 is H, C(O)Rb1, CO2Rb1, C(O)NRb1Rb2, C(S)NRb1Rb2, or SO2Rb1; each of R2 and R3, independently, is H or C1-C15 alkyl; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; each of R4 and R5, independently, is H or C1-C15 alkyl; one of R6 and R7 is C1-C15 alkyl substituted with C3-C20 heterocycloalkyl, and the other of R6 and R7 is H; R8 is H; and each of R9 and R10, independently, is H or CO2Re1. In this compound, one of R6 and R7 can be
- one of R2 and R3 can be H or C1-C15 alkyl optionally substituted with halogen, heteroaryl, aryl, ORc1, SRc1, OC(O)Rc1, CO2Rc1, C(O)NRc1Rc2, NRc1Rc2, N(Rc1)—CO2Rc2, N(Rc1)—C(O)Rc2, N(Rc1)—C(O)—NRc2Rc3, N(Rc1)—SO2Rc2, SO2Rc1, or O—SO2—Rc1; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; in which Rc3 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl; and one of R4 and R5 can be H or C1-C15 alkyl optionally substituted with halogen, aryl, ORf1, SRf1, CO2Rf1, C(O)NRf1Rf2, SO2Rf1, SO3Rf1, or NRf1Rf2; in which each of Rf1 and Rf2, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl.
- The term “treating” refers to administering one or more compounds of the invention to a subject, who has an infection with a virus, a symptom of such an infection, or a predisposition toward such an infection, with the purpose to confer a therapeutic effect, e.g., to cure, relieve, alter, affect, ameliorate, or prevent the infection with a virus, the symptom of it, or die predisposition toward it. The term “an effective amount” refers to the amount of one or more active compounds of the invention that is required to confer a therapeutic effect on a treated subject.
- The term “alkyl” refers to a saturated or unsaturated, linear or branched, non-aromatic hydrocarbon moiety, such as —CH3, —CH2—, —CH2—CH═CH2—, or branched —C3H7. The term “cycloalkyl” refers to a saturated or unsaturated, non-aromatic, cyclic hydrocarbon moiety, such as cyclohexyl or cyclohexen-3-yl. The term “heterocycloalkyl” refers to a saturated or unsaturated, non-aromatic, cyclic moiety having at least one ring heteroatom, such as 4-tetrahydropyranyl or 4-pyranyl. The term “aryl” refers to a hydrocarbon moiety having one or more aromatic rings. Examples of an aryl moiety include phenyl, phenylene, naphthyl, naphthylene, pyrenyl, anthryl, and phenanthryl. The term “heteroaryl” refers to a moiety having one or more aromatic rings that contain at least one heteroatom. Examples of a heteroaryl moiety include furyl, furylene, fluorenyl, pyrrolyl, thienyl, oxazolyl, imidazolyl, thiazolyl pyridyl pyrimidinyl, quinazolinyl, quinolyl, isoquinolyl and indolyl.
- Alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl mentioned herein include both substituted and unsubstituted moieties, unless specified otherwise. Examples of substituents on cycloalkyl, heterocycloalkyl, aryl, and heteroaryl include C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C1-C10 alkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, amino, C1-C10 alkylamino, C1-C20 dialkylamino, arylamino, diarylamino, hydroxyl, halogen, thio, C1-C10 alkylthio, arylthio, C1-C10 alkylsulfonyl, arylsulfonyl, cyano, nitro, acyl, acyloxy, carboxyl, and carboxylic ester. On the other hand, examples of substituents on alkyl include all of the above-recited substituents except C1-C10 alkyl, C2-C10 alkenyl, and C2-C10 alkynyl. Cycloalkyl, heterocycloalkyl, aryl, and heteroaryl also include fused groups.
- In another aspect, this invention features a method for inhibiting a viral protease (e.g., a coronaviral 3CL protease or a hepatitis C viral protease) in a cell. The method includes contacting the cell with an effective amount of a compound of formula (I) shown above. In particular, this invention features a method for inhibiting a severe acute respiratory syndrome viral 3CL protease, a human coronaviral 229E protease, or a hepatitis C viral protease.
- In still another aspect, this invention features a compound of formula (I) shown above except that R1 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, C(O)Rb1, CO2Rb2, C(O)NRb3Rb4, C(O)—N(Rb3)—ORb4, C(S)Rb3, C(S)NRb3Rb4, S(O)Rb3, SO2Rb3, S(O)NRb3Rb4, S(O)—N(Rb3)—ORb4, SO2NRb3Rb4, or SO3Rb3; in which Rb1 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, 6-membered heteroaryl, fused heteroaryl, aryl, or NHCO2Rb5; Rb2 is H, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, aryl, heteroaryl, or C1-C15 alkyl optionally substituted with halogen, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl heteroaryl, ORb5, CO2Rb5, or S(O)2Rb5; and each of Rb3 and Rb4, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl C3-C20 heterocycloalkyl heteroaryl, or aryl; Rb5 being H, C1-C15 alkyl, heteroaryl, or aryl.
- Referring to formula (I), a subset of the just-described compounds are those in which X is N(Ra1); or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; R1 is H, C(O)Rb1, CO2Rb2, C(O)NRb1Rb2, C(S)NRb1Rb2, or SO2Rb1, in which Rb1 is H, aryl, or C1-C15 alkyl optionally substituted with halogen, aryl, or NHCO2Rb5; and Rb2 is aryl or C1-C15 alkyl optionally substituted with halogen, ORb5, or CO2Rb5; each of R2 and R3, independently, is H or C1-C15 alkyl optionally substituted with ORc1, C(O)—NRc1Rc2, NRc1Rc2, N(Rc1)—CO2Rc2, N(Rc1)—SO2Rc2, or O—SO2—Rc1; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; each of R4 and R5, independently, is H or C1-C15 alkyl; one of R6 and R7 is C1-C15 alkyl substituted with C3-C20 heterocycloalkyl, and the other of R6 and R7 is H; R8 is H; and each of R9 and R10, independently, is H or CO2Rc1. In these compounds, one of R6 and R7 can be
- and one of R4 and R5 can be H or C1-C15 alkyl optionally substituted with aryl.
- In still another aspect, this invention features a compound of formula (I) shown above except, that R1 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, C(O)Rb1, CO2Rb2, C(O)NRb2Rb3, C(O)—N(Rb2)—ORb3, C(S)Rb2, C(S)NRb2Rb3, S(O)Rb2, SO2Rb2, S(O)NRb2Rb3, S(O)—N(Rb2)—ORb3, SO2NRb2Rb3, or SO3Rb2; in which Rb1 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, aryl, 6-membered heteroaryl, or fused heteroaryl; and each of Rb2 and Rb3, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, aryl, or heteroaryl; and one of R2 and R3 is C1-C15 alkyl substituted with halogen, ORc1, SRc1, CO2Rc1, OC(O)Rc1, C(O)NRc1Rc2, SO2Rc1, O—SO2—Rc1, NRc1Rc2, N(Rc1)—C(O)Rc2, N(Rc1)—CO2Rc2, N(Rc1)—SO2Rc2, N(Rc1)—C(O)—N(Rc2Rc3); the other of R2 and R3 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, ORc1, SRc1, or NRc1Rc2; in which each of Rc1, Rc2, and Rc3, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl.
- Referring to formula (I), a subset of the just-described compounds are those in which X is N(Ra1) or O; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; R1 is CO2Rb2, in which Rb2 is alkyl substituted with aryl; one of R2 and R3 is C1-C15 alkyl substituted with ORc1, SRc1, OC(O)Rc1, CO2Rc1, C(O)NRc1Rc2, SO2Rc1, O—SO2—Rc1, NRc1Rc2, N(Rc1)—C(O)Rc2, N(Rc1)—CO2Rc2, N(Rc1)—SO2Rc2, N(Rc1)—C(O)—N(Rc2Rc3), and the other of R2 and R3 is H; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; each of R4 and R5, independently, is H or C1-C15 alkyl; one of R6 and R7 is C1-C15 alkyl substituted with C3-C20 heterocycloalkyl, and the other of R6 and R7 is H; R8 is H; and each of R9 and R10, independently, is H, CN, C(O)Re1, CO2Re1, or C(O)NRe1Re2; or R9 and R10, taken together, are C3-C20 heterocycloalkyl. In these compounds, one of R6 and R7 can be
- and one of R4 and R5 can be H or C1-C15 alkyl optionally substituted with aryl, C3-C20 cycloalkyl, ORf1, SRf1, NRf1Rf2, or C(O)NRf1Rf2; in which each of Rf1 and Rf2, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl.
- In still another aspect, this invention features a compound of formula (I) shown above except that R1 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, C(O)Rb1, CO2Rb2, C(O)NRb2Rb3, C(O)—N(Rb2)—ORb3, C(S)Rb2, C(S)NRb2Rb3, S(O)Rb2, SO2Rb2, S(O)NRb2Rb3, S(O)—N(Rb2)—ORb3, SO2NRb2Rb3, or SO3Rb2; in which Rb1 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, aryl, 6-membered heteroaryl, or fused heteroaryl; and each of Rb2 and Rb3, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, aryl, or heteroaryl; one of R4 and R5 is C1-C15 alkyl substituted with halogen, ORd1, SRd1, CO2Rd1, C(O)NRd1Rd2, SO2Rd1, SO3Rd1, or NRd1Rd2; the other of R4 and R5 is H, halogen, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl; in which each of Rd1 and Rd2, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl; R8 is H, halogen, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, ORe1, or SRe1; in which Re1 is H and C1-C15 alkyl; and each of R9 and R10, independently, is H, halogen, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, C(O)Rf1, CO2Rf1, C(O)NRf1Rf2, C(O)—N(Rf1)—ORf2, C(S)Rf1, C(S)NRf1Rf2, CN, NO2, S(O)Rf1, SO2Rf1, S(O)NRf1Rf2, S(O)—N(Rf1)—ORf2, SO2NRf1Rf2, SO3Rf1, PO(ORf1)(ORf2), PO(Rf1)(Rf2), PO(NRf1Rf2)(ORf3), PO(NRf1Rf2)(NRf3Rf4), C(O)—N(Rf1)—NRf2Rf3, or C(S)—N(Rf1)—NRf2Rf3; or R8 and R10, taken together, is C3-C20 cycloalkyl or C3-C20 heterocycloalkyl; or R9 and R10, taken together, is C3-C20 cycloalkyl or C3-C20 heterocycloalkyl; in which each of Rf1, Rf2, Rf3, and Rf4, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl; or any two of Rf1, Rf2, Rf3, and Rf4, together with the atom or atoms to which they are bonded, is C3-C20 heterocycloalkyl.
- Referring to formula (I), a subset of the just-described compounds are those in which X is N(Ra1) or O; R1 is CO2Rb2, in which Rb2 is alkyl substituted with aryl; each of R2 and R3, independently, is H or C1-C15 alkyl optionally substituted with aryl; one of R4 and R5 is C1-C15 alkyl substituted with SRd1 or C(O)NRd1Rd2, and the other of R4 and R5 is H; one of R6 and R7 is C1-C15 alkyl substituted with C3-C20 heterocycloalkyl, and the other of R6 and R7 is H; R8 is H; and each of R9 and R10, independently, is H or CO2Rf1. In these compounds, one of R6 and R7 can be
- In a further aspect, this invention features a method for treating an infection with a virus. The method includes administering to a subject in need thereof an effective amount of a compound of formula (II):
- In this formula, X is N(Ra1), O, or CH2; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; in which Ra1 is H or C1-C15 alkyl; R1 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, C(O)Rb1, CO2Rb1, C(O)NRb1Rb2, C(O)—N(Rb1)—ORb2, C(S)Rb1, C(S)NRb1Rb2, S(O)Rb1, SO2Rb1, S(O)NRb1Rb2, S(O)—N(Rb1)—ORb2, SO2NRb1Rb2, or SO3Rb1; in which each of Rb1 and Rb2, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl; each of R2 and R3, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, ORc1, SRc1, or NRc1Rc2; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; in which each of Rc1 and Rc2, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl; each of R4 and R5, independently, is H, halogen, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl; and one of R6, R7, and R8 is C1-C15 alkyl substituted with C3-C20 heterocycloalkyl, heteroaryl, or aryl; and the others of R6, R7, and R8, independently, is H, halogen, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, ORd1, SRd1, C(O)Rd, CO2Rd1, C(O)NRd1Rd2, or C(O)—N(Rd1)—ORd2; in which Rd1 and Rd2, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl; and the virus is a coronavirus or a hepatitis C virus.
- In particular, this invention features a method for treating an infection with a severe acute respiratory syndrome virus, a human coronavirus 229E, or a hepatitis C virus, by administering to a subject in need thereof an effective amount of a compound of formula (II) shown above.
- For example, one can administer to a subject infected with a virus (e.g., a severe acute respiratory syndrome virus) a compound of formula (II), in which X is N(Ra1) or O; R1 is CO2Rb1, in which Rb1 is alkyl substituted with aryl; each of R2 and R3, independently, is H or C1-C15 alkyl optionally substituted with aryl, ORc1, CO2Rc1, N(Rc1)—C(O)Rc2, or OC(O)—NRc1Rc2; each of R4 and R5, independently, is H or C1-C15 alkyl; R6 is C1-C15 alkyl substituted with C3-C20 heterocycloalkyl; R7 is H; and R8 is C(O)Rd1, CO2Rd1, C(O)NRd1Rd2, or C1-C15 alkyl optionally substituted with halogen or OH. In these compounds, one of R6 and R7 can be
- In a further aspect, this invention features a method for inhibiting a viral protease (e.g., a coronaviral 3CL protease or a hepatitis C viral protease) in a cell, by contacting the cell with an effective amount of a compound of formula (II) shown above. In particular, this invention features a method for inhibiting a severe acute respiratory syndrome viral 3CL protease, a human coronaviral 229E protease, or a hepatitis C viral protease.
- In a further aspect, this invention features a compound of formula (II) shown above.
- In still a further aspect, this Invention features a method for treating an infection with a picornavirus (e.g., an enterovirus or a rhinovirus). The method includes administering to a subject in need thereof an effective amount of a compound of formula (I) or a compound of formula (II).
- In still a further aspect, this invention features a method for inhibiting a picornaviral protease (e.g., an enteroviral protease or a rhinoviral 3C protease) In a cell. The method includes contacting the cell with an effective amount of a compound of formula (I) or a compound of formula (II).
- In yet a further aspect, this invention features a chemical synthetic method. The method includes reducing a compound of formula (III):
- to form an alcohol, followed by reacting the alcohol with Ph3P═COOR in the presence of pyridine sulfur trioxide to give a compound of formula (IV):
- in which P1 is an amino-protecting group; P2 is a carboxyl-protecting group; and R is C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl. In formulas (III) and (IV), P1 can be t-butoxycarbonyl, benzyloxycarbonyl, acetyl, phenylcarbonyl, or trialkylsilyl; P2 can be C1-C15 alkyl; and R can be C1-C15 alkyl.
- In particular, the chemical synthetic method can further include removing the amino-protecting group P1 of the compound of formula (IV) to form a first de-protected intermediate, and then reacting the first de-protected intermediate with P3HN—CH(R5)—COOH to give a compound of formula (V):
- in which P3 is an amino-protecting group and R5 is H, halogen, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl. The method can further include removing the amino-protecting group P3 of the compound of formula (V) to form a second de-protected intermediate, and then reacting the second de-protected intermediate with R1HN—CH(R2)—COOH to give a compound of formula (VI):
- in which R1 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, C(O)Rb1, CO2Rb1, C(O)NRb1Rb2, C(O)—N(Rb1)—ORb2, C(S)Rb1, C(S)NRb1Rb2, S(O)Rb1, SO2Rb1, S(O)NRb1Rb2, S(O)—N(Rb1)—ORb2, SO2NRb1Rb2, or SO3Rb1; in which each of Rb1 and Rb2, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl; and R2 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, ORc1, SRc1, or NRc1Rc2; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; in which each of Rc1 and Rc2, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl. In formulas (V) and (VI), P3 can be t-butoxycarbonyl, benzyloxycarbonyl, acetyl, phenylcarbonyl, or trialkylsilyl; and R can be C1-C15 alkyl.
- Alternatively, the chemical synthetic method mentioned above can further include removing the amino-protecting group P1 of the compound of formula (IV) to form a first de-protected intermediate, and then reacting the first de-protected intermediate with a compound of formula (VII):
- to give a compound of formula (VI):
- in which R1 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, C(O)Rb1, CO2Rb1, C(O)NRb1Rb2, C(O)—N(Rb1)—ORb2, C(S)Rb1, C(S)NRb1Rb2, S(O)Rb1, SO2Rb1, S(O)NRb1Rb2, S(O)—N(Rb1)—ORb2, SO2NRb1Rb2, or SO3Rb1; in which each of Rb1 and Rb2, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl; R2 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, ORc1, SRc1, or NRc1Rc2; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; in which each of Rc1 and Rc2, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl; and R5 is H, halogen, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl or aryl.
- In addition, the chemical synthetic method can further include removing the amino-protecting group P1 of the compound of formula (IV) to form a first de-protected intermediate, and then reacting the first de-protected intermediate with a compound of formula (VIII):
- in which n is 1, 2, or 3; P4 is an amino-protecting group; and R5 is H, halogen, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl heteroaryl, or aryl; followed by removing the amino-protecting group P4 to give a compound of formula (IX):
-
- in which R1′ is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, or ORb1; Rb1 being H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl. In formulas (VIII), (IX), and (X), P4 can be t-butoxycarbonyl, benzyloxycarbonyl, acetyl, phenylcarbonyl, or trialkylsilyl; and R can be C1-C15 alkyl.
- In addition, this invention encompasses a pharmaceutical composition that contains an effective amount of at least one of the above-mentioned compounds and a pharmaceutically acceptable carrier.
- The compounds of the invention include the compounds themselves, as well as their salts, prodrugs, and solvates, if applicable. A salt, for example, can be formed between an anion and a positively charged group (e.g., amino) on a compound of the invention. Examples of suitable anions include chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, and acetate. Likewise, a salt can also be formed between a cation and a negatively charged group (e.g., carboxylate) on a compound of the Invention. Examples of suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethyl ammonium ion. Examples of prodrugs include esters and other pharmaceutically acceptable derivatives, which, upon administration to a subject, are capable of providing active compounds of the invention. A solvate refers to a complex formed between an active compound of the invention and a pharmaceutically acceptable solvent. Examples of pharmaceutically acceptable solvents include water, ethanol, isopropanol, ethyl acetate, acetic acid, and ethanolamine.
- Also within the scope of this invention is a composition containing one or more of the compounds described above for use in treating an infection with a virus, and the use of such a composition for the manufacture of a medicament for the just-mentioned treatment.
- The details of one or more embodiments of the invention are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the description and from the claims.
- Shown below are the structures of compounds 1-145, exemplary compounds of this invention:
- The compounds described above can be prepared by methods well known, to a skilled person in the art. For example, Schemes I-IV shown below depict typical synthetic routes for preparing exemplary compounds, in these schemes, R1, R1′, R2, and R5 are as defined in the Summary section above. Details of preparation of these compounds are provided in Examples 1-145.
- As shown in Scheme I, L-glutamic acid can first be protected with t-butoxylcarbonyl and methyl. The protected L-glutamic acid (intermediate 1) can then react with bromoacetonitrile and followed by a ring closure reaction to form an amino acid derivative that containing a 5-membered cyclic lactam (intermediate 3). Intermediate 3 can subsequently be transformed to intermediate 5 that includes an additional double bond. Intermediate 5 thus formed can sequentially couple with two amino acid derivatives to prepare a compound of formula (I). Reagents other than those shown in Scheme I can also be used. For example, intermediate 5 mentioned above can couple with an acid containing hydroxyl, before coupling to an amino acid to prepare a compound of formula (I) in which X is oxygen.
- As shown in Scheme II, intermediate 5 can also couple with amino acid derivatives that contain a pyrrolidinone moiety to form certain compounds of formula (IX). The compounds thus obtained can be further modified (e.g., by reacting with an acid or an acyl chloride) to obtain compounds of formula (X).
- As shown in Scheme III, intermediate 5 can also be hydrolyzed to form an acid, which in turn can react with O,N-dimethyl-hydroxylamine to form an amide. The amide can either sequentially couple with two amino acid derivatives or couple with a dipeptide derivative to form certain compounds of formula (I). The compounds thus obtained can further react with Grignard reagents to form other compounds of formula (I).
- As shown in Scheme IV, intermediate 3 mentioned above can also sequentially couple with two amino acid derivatives (or couple with a dipeptide derivative) to form certain compounds of formula (I). The compounds thus obtained can be further reduced to form alcohols or oxidized to form acids. The alcohols can be further halogenated to form halides or oxidized to form aldehydes. The aldehydes can subsequently undergo either Wittig reactions or addition-elimination reactions to form certain compounds of formula (II). The acids just-mentioned can undergo, e.g., esterification reactions, Grignard reactions, or amidation reactions to form other compounds of formula (II).
- A compound synthesized by the methods described above can be purified by a known method, such as column chromatography, high-pressure liquid chromatography, or recrystallization.
- Other compounds of the invention can be prepared using other suitable starting materials following the synthetic routes disclosed herein and/or other synthetic methods known in the art. The methods described above may also additionally include steps, either before or after the steps described specifically herein, to add or remove suitable protecting groups in order to ultimately allow synthesis of the compounds of the invention. In addition, various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing applicable compounds of the invention are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2nd Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed. Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995) and subsequent editions thereof.
- The compounds mentioned herein may contain a non-aromatic double bond and one or more asymmetric centers. Thus, they can occur as racemates and racemic mixtures, single enantiomers, individual diastereomers, diastereomeric mixtures, and cis- or trans-isomeric forms. All such isomeric forms are contemplated.
- Also within the scope of this invention is a pharmaceutical composition contains an effective amount of at least one compound described above and a pharmaceutical acceptable carrier. Further, this invention covers a method of administering an effective amount of one or more of the compounds of the invention to a patient having an infection with a coronavirus. Effective doses will vary, as recognized by those skilled in the art, depending on the types of diseases treated, route of administration, excipient usage, and the possibility of co-usage with other therapeutic treatment.
- To practice the method of the present invention, a composition having one or more compounds of the invention can be administered parenterally, orally, nasally, rectally, topically, or buccally. The term “parenteral” as used herein refers to subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional, or intracranial injection, as well as any suitable infusion technique.
- A sterile injectable composition can be a solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are mannitol, water, Ringer's solution, and isotonic sodium chloride solution. In addition, fixed oils are conventionally employed as a solvent or suspending medium (e.g., synthetic mono- or diglycerides). Fatty acid, such as oleic acid and its glyceride derivatives are useful in the preparation, of injectables, as are natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions can also contain a long chain alcohol diluent or dispersant, carboxymethyl cellulose, or similar dispersing agents. Other commonly used surfactants such as Tweens or Spans or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms can also be used for the purpose of formulation.
- A composition for oral administration can be any orally acceptable dosage form including capsules, tablets, emulsions and aqueous suspensions, dispersions, and solutions. In the case of tablets, commonly used carriers include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions or emulsions are administered orally, the active ingredient can be suspended or dissolved in an oily phase combined with emulsifying or suspending agents. If desired, certain sweetening, flavoring, or coloring agents can be added.
- A nasal aerosol or inhalation composition can be prepared according to techniques well known in the art of pharmaceutical formulation. For example, such a composition can be prepared as a solution in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art. A composition having one or more compounds of the invention can also be administered in the form of suppositories for rectal administration.
- The carrier in the pharmaceutical composition must be “acceptable” in the sense that it is compatible with the active ingredient of the composition (and preferably, capable of stabilizing the active ingredient) and not deleterious to the subject to be treated. One or more solubilizing agents can be utilized as pharmaceutical excipients for delivery of a compound of the invention. Examples of other carriers include colloidal silicon oxide, magnesium stearate, cellulose, sodium lauryl sulfate, and D&C Yellow # 10.
- The compounds of this invention can be preliminarily screened for their efficacy in treating an infection with a virus by an in vitro assay (See Example 146 below) and then confirmed by animal experiments and clinic trials. Other methods will also be apparent to those of ordinary skill in the art.
- The specific examples below are to be construed, as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. All publications cited herein, are hereby incorporated by reference in their entirety.
- TMSC1 (190 mL, 4.4 eq) was slowly added to a stirred suspension of L-glutamic acid (50.0 g, 1 eq.) in dry MeOH (1100 mL, 0.3 M) surrounded by an ice-cold bath. After the addition was complete, the ice-cold bath was removed and the reaction was stirred overnight until TLC showed completed conversion. Then, Et3N (306 mL, 6.5 eq) and (Boc)2O (82 g, 1.1 eq) were added sequentially to the above reaction mixture. The reaction mixture was then stirred until TLC showed complete protection. The solvent was removed under reduced pressure. The residue was then filtered and washed with Et2O using a pad of celite. The organic layers were combined and concentrated. The resulting crude product was purified by silica get column chromatography to afford intermediate 1, N-Boc-L-(+)-glutamic acid dimethyl ester, (88 g, 95%) as an oil: 1H NMR (CDCl3) δ 1.40 (s, 9H), 1.91 (m, 1H), 2.14 (m, 2H), 2.37 (m, 2H), 3.64 (s, 3H), 3.70 (s, 3H), 4.29 (br, s, 1H). ESI-MS (M+H+)=276.
- To a solution of intermediate 1 (20 g, 1 eq.) in THF (50 mL) was added dropwise a solution of lithium hexamethyldisilazide (2.2 eq.) in THF (250 mL) at −78° C. under nitrogen atmosphere. The resulting mixture was stirred at −78° C. for another 1.5 hours. Bromoacetonitrile (13 g, 1.5 eq.) was added dropwise to the above solution over a period of 1 hour while maintaining the temperature below −70° C. using a cooling bath. The reaction mixture was stirred at −78° C. for additional for 1-2 hours and the disappearance of the starting material was confirmed by TLC analysis. The reaction was then quenched with pre-cooled methanol (10 mL) stirred for 10 minutes. The resulting methoxide was then quenched with a pre-cooled acetic acid in THF solution (9 mL HOAc/60 mL THF). After stirred for another 10 minutes, the cooling bath was removed and replaced with water bath. The reaction mixture was allowed to warm up to 0±5° C. and then poured into brine solution (10 g of NaCl in 100 mL water) in a 1 L extractor. The organic layer was separated and concentrated to afford a dark brown oil. Silica gel (25 g) and methylene chloride (60 mL) were added to the Rotovap flask and spun on a Rotovap for 1 hour without heat and vacuum. The slurry was then filtered and wash with another batch of methylene chloride (100 mL). The light brown filtrate was collected, concentrated, and purified by silica gel column chromatography to afford intermediate 2 (19 g), 2-tert-butoxycarbonyl-amino-4-cyanomethyl-pentanedioic acid dimethyl ester. 1H NMR (CDCl3) δ 1.42 (s, 9H) 2.10-2.17 (m, 2H), 2.77-2.90 (m, 3H), 3.73 (s, 3H), 3.74 (s, 3H), 4.32-4.49 (m, 1H), 5.12 (d, J=6.0 Hz, 1H). ESI-MS (M+H+)=315.
- Intermediate 2 (10 g) was dissolved in HOAc (240 mL) and shaken with 10% Pd/C (20 g) under H2 gas (70 psi) for 2 days. The mixture was filtered over celite. The filtrate was evaporated under reduced pressure and the residue was repeatedly evaporated from methyl tert-butyl ether to yield a light pink solid. The crude product was dissolved in THF and then Et3N (20 mL) was added to the solution. The resulting mixture was stirred at 60° C. overnight. The reaction was quenched with by addition of H2O (50 mL). The organic layer was separated and the aqueous layer was further extracted with methylene chloride. The organic layers were then combined, concentrated, and purified by silica gel column chromatography to afford intermediate 3,2-tert-butoxycarbonylamino-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester. 1H NMR (CDCl3) δ 1.37 (s, 9H), 1.75-1.80 (m, 2H), 2.04-2.09 (m, 1H), 2.39-2.42 (m, 1H), 3.25-3.29 (m, 2H), 3.67 (s, 3H), 4.23-4.26 (m, 1H), 5.47 (d, J=8.0 Hz, 1H), 6.29 (s, 1H). ESI-MS (M+H+)=287.
- Intermediate 3 (6.0 g, 18.4 mmol) was solved in THF (200 mL) surrounded by an ice bath, followed by addition of 2.0 M LiBH4/THF (46 ml, 5.0 eq). The ice bath was then removed and the mixture was stirred for 2 hours at room temperature. To the mixture was sequentialled added water (200 mL), ethyl acetate (200 mL), and MgSO4 (400 g). Then MgSO4 was removed and the aqueous layer was extracted with ethyl acetate. The organic layers were combined and concentrated to afford intermediate 4, [2-hydroxy-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethyl]-carbamic acid tert-butyl ester, as a white solid (5.2 g, 95%). ESI-MS (M+H+)=259.
- Triethylamine (0.7 mL) was added to a solution of intermediate 4 (0.59 g, 2.28 mmol, 1 eq.) in methylsulfoxide (10.5 mL). The resulting solution was cooled to 15° C. using an ice-water bath and then sulfur trioxide-pyridine complex (1.8 g, 5 eq.) was added. The reaction was stirred at that temperature for 1 hour.
- (Carboethoxymethylenetriphenyl)-phosphorane (2.4 g, 3 eq.) was added and the reaction was stirred at ambient temperature for another 3 hours. The reaction was then quenched by saturated brine (150 mL) and extracted with ethyl acetate (3×50 mL). The organic layers were combined, dried over anhydrous MgSO4, filtered, and concentrated to afford a dark red oil. The oil was purified though column chromatography (50% ethyl acetate in hexane) to afford intermediate 5,4-tert-butoxycarbonylamino-5-(2-oxo-pyrrolidin-3-yl)-pent-2-enoic acid ethyl ester, as a white solid (0.34 g, 45.7%), 1H NMR (CDCl3) δ 1.21 (t, 3H, J=7.2), 1.36 (s, 9H), 1.48-1.57 (m, 1H), 1.66-1.79 (m, 1H), 1.90-1.97 (m, 1H), 2.38-2.47 (m, 2H), 3.26-3.29 (m, 2H), 4.10 (q, 2H, J=6.9), 4.27 (s, br, 1H), 5.46 (d, 1H, J=7.5), 5.87 (d, 1H, J=15.6), 6.78 (dd, 1H, J=15.3, J=5.4), 6.98 (s, br, 1H). ESI-MS (M+H+)=577.
- Intermediate 5 (100 mg, 0.3 mmol) was added to a solution of HCl in 1,4-dioxane (4.0 M, 3 mL) and the solution was stirred at room temperature for 30 minutes. The resulting solution was concentrated by removing 1,4-dioxane. CH2Cl2 (3 mL) was then added to the residue thus obtained and the solution was cooled down to 0-5° C. N-Methylmorpholine (0.13 mL, 4 eq.) was then added and the mixture was stirred for 10 minutes to form solution (a). Boc-L-Leu-OH (71 mg, 0.3 mmol) was mixed with 1,1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, 70 mg, 1.2 eq.) and N-hydroxybenzotriazole (HOBt, 50 mg, 1.2 eq.) in CH2Cl2. The mixture was stirred for 20 minutes to form solution (b). Solution (a) was then added to solution (b) and the mixture was stirred, at room temperature for 2 hours. The reaction residue was added with brine (25 mL) and extracted with ethyl acetate (3×15 mL). The organic layers were combined, dried over anhydrous MgSO4, and concentrated. The residue was purified by flash column chromatography (3% MeOH in CH2Cl2) to afford intermediate 6,4-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)-5-(2-oxo-pyrrolidin-3-yl)-pent-2-enoic acid ethyl ester, as a white solid. 1H NMR (CDCl3) δ 0.94 (d, 6H, J=5.1 Hz), 1.26 (t, 3H, J=7.2 Hz), 1,43 (s, 9H), 1.66-1.73 (m, 5H), 2.41 (br s, 1H), 3.33 (d, 2H, J=8.1 Hz), 4.16 (q, 2H, J=6.9 Hz), 4.58 (br, s, 1H), 5.03 (br, s, 1H), 5.9 (d, 1H, J=15.6 Hz), 6.82 (dd, 1H, J=15.3 Hz, 5.1 Hz), 7.50 (br, s, 1H). ESI-MS (M+H+)=440.
- Intermediate 7 (compound 6) was prepared in 60% yield from 2-benzyloxycarbonyl-amino-3-tert-butoxy-butyric acid and intermediate 6 using the procedure similar to that described in the preceding paragraph. 1H NMR (CDCl3) δ 0.94-0.98 (m, 6H), 1.07 (d, 3H, J=6.3), 1.27 (s, 9H), 1.66-1.73 (m, 5H), 2.21-2.50 (m, 2H), 3.20-3.30 (m, 2H), 4.16 (q, 2H, J=6.9 Hz), 4.42 (br, s, 1H), 4.58 (br, s, 1H) 5.10 (s, 2H), 5.9 (d, 1H, J=15.6 Hz), 6.82 (dd, 1H, J=15.3 Hz, 5.1 Hz), 7.2-7.34 (m, 4H), 7.60 (d, 1H, J=7.5 Hz). ESI-MS (M+H+)=631.
- Compound 1 was prepared by treating intermediate 7 with trifluoroacetic acid (2 mL). 1H NMR (CDCl3) δ 0.89-0.93 (m, 6H), 1.13-1.15 (m, 3H), 1.22-1.27 (m, 3H), 1.55-1.76 (m, 4H), 1.95-2 (m, 1H), 2.03-2.46 (m, 2H), 3.28-3.30 (m, 2H), 4.11-4.18 (m, 3H), 4.33 (br s, 1H), 4.54-4.56 (br s, 2H), 5.07 (s, 2H), 5.84-5.94 (d, 1H, J=15.9 Hz), 6.03-6.06 (d, J=7.2 Hz), 6.76-6.83 (dd, 1H, J=15.0 Hz, 5.4 Hz), 7.31 (br s, 5H), 8.02 (br s, 1H). ESI-MS (M+H+)=575.
- Compound 2 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 7.92 (d, J=7.5 Hz, 1H), 7.24-7.38 (m, 5H), 6.78 (dd, J=15, 2.7 Hz, 1H), 5.98 (d, J=7.8 Hz, 1H), 5.89 (d, J=15 Hz, 1H), 5.09 (d, J=4.2 Hz, 1H), 5.07 (s, 2H), 4.60-4.78 (m, 1H), 4.43-4.53 (m, 2H), 4.21-4.38 (m, 1H), 4.17 (q, J=5.1 Hz, 2H), 3.82-3.88 (m, 1H), 3.40-3.71 (m, 2H), 3.29 (m, 2H), 1.40-2.11 (m, 5H), 1.25 (t, J=5.1 Hz), 0.90 (br s, 6H).
- ESI-MS (M+H+)=561.
- Compound 3 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.91 (s, br, 6H), 1.27 (t, 3H, J=6.0), 1.60-1.66 (m, 5H), 1.97-2.44 (m, 7H), 3.26 (m, 2H), 4.17 (q, 2H, J=6.9), 4.24 (m, 1H) 4.60 (m, 1H), 5.06 (s, 2H), 5.92 (d, 1H, J=15.3), 6.12-6.18 (m, 2H), 6.62-6.70 (m, 1H), 6.83 (dd, 1H, J=15.3, 5.), 7.31 (s, br, 5H), 7.56 (m, 1H), 8.01 (m, 1H).
- ESI-MS (M+Na+)=623.9.
- Compound 4 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 7.82 (d, J=8.0 Hz, 1H), 6.90 (d, J=7.5 Hz, 1H), 6.82 (dd, J=15, 5.4 Hz, 1H), 5.89 (m, 4H), 5.09 (m, 2H), 4.40-4.68 (m, 2H), 4.16 (q, J=7.5 Hz, 2H), 3.32 (m, 2H), 2.03-2.51 (m, 2H), 1.50-2.03 (m, 10H), 1.43 (s, 9H), 1.69 (t, J=7.5 Hz, 3H), 0.94 (d, J=6.0 Hz, 3H), 0.92 (d, J=6.0 Hz, 3H).
- ESI-MS (M+H+)=659.
- Compound 5 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CD3OD) δ 0.86-1.04 (m, 6H), 1.23 (s, br, 3H), 1.60-1.71 (m, 6H), 2.06-2.85 (m, 6H), 3.38 (m, 2H), 4.10-4.28 (m, 2H), 4.34-4.45 (m, 1H), 4.60-4.72 (m, 1H), 5.13 (s, 2H), 5.91 (d, 1H, J=15.9), 6.82 (dd, 1H, J=15.9, 4.7), 7.27-7.54 (m, 5H).
- ESI-MS (M+H+)=589.
- Compound 6 was prepared in a manner identical to that of intermediate 7 described in Example 1.
- 1H NMR (CDCl3) δ 0.94-0.98 (m, 6H), 1.07 (d, 3H, J=6.3), 1.27 (s, 9H), 1.66-1.73 (m, 5H), 2.21-2.50 (m, 2H), 3.20-3.30 (m, 2H), 4.16 (q, 2H, J=6.9 Hz), 4.42 (br, s, 1H), 4.58 (br, s, 1H), 5.10 (s, 2H), 5.9 (d, 1H, J=15.6 Hz), 6.82 (dd, 1H, J=15.3 Hz, 5.1 Hz), 7.2-7.34 (m, 4H), 7.60 (d, 1H, J=7.5 Hz).
- ESI-MS (M+H+)=631.
- Compound 7 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.86-0.87 (d, 6H, J=4.2), 1.09 (s, 9H), 1.18-1.22 (t, 3H, J=7.2), 1.66 (m, 5H), 2.30 (s, br, 2H), 3.21-3.24 (d, 2H, J=7.2), 3.35-3.40 (t, 1H, J=6.6), 3.74-3.76 (d, 1H, J=6.9), 4.10 (q, 2H, J=7.2), 4.16 (s, br, 1H), 4.51 (s, br, 2H), 5.03-5.05 (d, 2H, J=4.8), 5.64-5.65 (d, 1H, J=15.9), 6.72-6.77 (dd, 1H, J=4.5), 6.93-6.96 (d, 1H, J=6.9), 7.28 (s, br, 5H), 7.60 (s, br, 1H).
- ESI-MS (M+H+)=616.
- Compound 8 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 7.74 (d, J=7.5 Hz, 1H), 7.24-7.33 (m, 10H), 7.05 (d, J=8.5 Hz, 1H), 6.80 (dd, J=15.5, 5.5 Hz, 1H), 6.17 (s, 1H), 5.90 (d, J=15.5 Hz, 1H), 5.73 (d, J=6.5 Hz, 1H), 5.10 (s, 2H), 4.47-4.62 (m, 4H), 4.27-4.29 (m, 1H), 4.18-4.20 (m, 3H), 3.24-3.27 (m, 2H), 2.23-2.48 (m, 2H), 1.90-2.14 (m, 1H), 1.89 (s, 2H), 1.47-1.73 (m, 3H), 1.26 (t, J=3.6 Hz, 3H), 1.21 (d, J=10.2 Hz, 3H), 0.87 (d, J=8.0 Hz, 3H), 0.85 (d, J=8.0 Hz 3H).
- ESI-MS (M+H+)=665.
- Compound 9 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=639.
- Compound 10 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.88-0.98 (m, 6H), 1.19-1.86 (m, 15H), 2.0-2.08 (m, 1H), 2.15-2.39 (m, 2H), 2.47-2.59 (m, 1H), 2.94 (m, 2H), 3.98-4.20 (m, 3H), 4.30-4.36 (m, 1H), 4.60-4.64 (m, 1H), 5.09 (m, 2H), 5.89 (d, J=15.6, 1H), 6.89 (dd, 1H, 15.6, 4.8), 7.26-7.33 (m, 5H).
- ESI-MS (M+H+)=639.
- Compound 11 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 7.90 (d, J=7.0 Hz, 1H), 7.31 (s, 5H), 6.77-6.85 (m, 2H), 6.41 9 (br, s, 1H), 5.90 (d, J=15 Hz, 1H), 5.78 (d, J=7 Hz, 1H), 5.07 (s, 2H), 4.87 (br, s, 1H), 4.41-4.62 (m, 2H), 4.07-4.14 (m, 4H), 3.21-3.37 (m, 2H), 2.94-3.18 (m, 2H), 2.28-2.48 (m, 3H), 1.28-2.13 (m, 10H), 1.39 (s, 9H), 1.26 (t, 4.5 Hz, 3H), 0.92 (d, J=6.3 Hz, 3H), 0.90 (d, J=6.3 Hz, 3H)
- ESI-MS (M+H+)=702.
- Compound 12 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=680.
- Compound 13 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 7.94 (d, J=7.0 Hz, 1H), 7.31 (s, 5H), 6.81 (dd, J=15, 5 Hz, 1H), 6.38 (br s, 1H), 5.84-5.93 (m, 2H), 5.31 (br s, 1H), 5.07 (s, 2H), 4.41-4.64 (m, 2H), 4.11-4.16 (m, 4H), 3.62-3.64 (m, 2H), 3.60 (s, 3H), 3.43-3.51 (m, 2H), 3.23-3.29 (m, 2H), 3.06-3.20 (m, 2H), 2.28-2.48 (m, 2H), 1.20-1.96 (m, 8H), 1.26 (t, J=4.5 Hz, 3H), 0.92 (d, J=6.5 Hz, 3H), 0.90 (d, J=6.5 Hz, 3H).
- ESI-MS (M+H+)=660.
- Compound 14 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.93 (m, 6H), 1.25-1.30 (m, 3H), 1.47-1.98 (m, 5H), 2.20-2.60 (m, 5H), 2.93 (3, 3H), 3.11-3.45 (m, 4H), 4.12-4.19 (m, 2H), 4.45-4.48 (m, 3H), 5.09 (s, 2H), 5.86-5.92 (d, 1H, J=15.9 Hz), 6.75-6.82 (dd, 1H, J=15.9 Hz, 5.1 Hz), 7.33-7.36 (m, 5H), 8.12 (br, s, 1H), 8.23 (br, s, 1H).
- ESI-MS (M+H+)=637.
- Compound 15 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=631.
- Compound 16 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.81-0.86 (m, 6H), 1.11-1.22 (m, 5H), 1.29-1.34 (m, 2H), 1.55-1.77 (m, 9H), 2.37 (s, br, 3H), 2.93 (s, 2H), 3.25 (s, br, 2H), 3.62-3.64 (m, 1H), 4.10 (q, 2H, J=6.6), 4.28-4.48 (m, 3H), 4.93-5.07 (m, 2H), 5.83 (d, 1H, J=15), 5.99 (s, 1H), 6.75 (dd, 1H, J=16.5, 6.3), 7.26 (s, br, 5H), 7.82 (m, 1H), 8.19 (s, 1H).
- Compound 17 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CD3OD) δ 0.92-1.00 (m, 6H), 1.18-1.33 (m, 15H), 1.58-1.82 (m, 6H), 2.02-2.35 (m, 4H), 3.20-3.32 (m, 2H), 4.14-4.32 (m, 4H), 4.62-4.66 (m, 1H), 5.07-5.13 (m, 2H), 5.29 (d, 1H, J=5.4), 5.92 (d, 1H, J=15.6), 6.88 (dd, 1H, J=15.6, 5.7), 7.29-7.36 (m, 5H).
- ESI-MS (M+H+)=632.
- Compound 18 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.90-0.92 (m, 12H), 3.65 (t, 3H, J=6.9), 1.50-1.61 (m, 4H), 1.77 (m, 1H), 2.01-2.07 (m, 3H), 2.37 (m, 2H), 3.27-3.36 (m, 2H), 3.65 (t, 2H, J=5.4), 3.96 (t, 1H, J=6.9), 4.15 (q, 2H, J=6.9), 4.30 (t, 2H, J=5.4), 4.60 (m, 2H), 5.60 (d, 1H, J=8.4), 5.89 (d, 1H, J=15.6), 6.64 (s, 1H), 6.80 (dd, 1H, J=15.6), 7.07 (d, 1H, J=7.8), 7.76 (d, 1H, J=7.5).
- ESI-MS (M+H+)=545.
- Compound 19 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.84-0.89 (m, 12H), 1.15-1.22 (m, 6H), 1.45-1.57 (m, 3H), 1.75 (s, br, 3H), 1.94-2.09 (m, 2H), 2.32 (s, br, 2H) 3.27 (d, 2H, J=7.8), 3.87 (t, 1H, J=6.9), 4.00-4.13 (m, 4H), 4.53 (s, br, 2H), 5.20 (d, 1H, J=8.4), 5.83 (d, 1H, J=15.3), 6.42 (s, 1H), 6.75 (dd, 1H, J=15.6, 5.4), 6.92 (d, 1H, J=8.1), 7.67 (d, 1H, J=7.2).
- ESI-MS (M+H+)=533.
- Compound 20 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.90-0.93 (m, 18H), 1.24-1.29 (t, 3H, J=5.4 Hz), 1.52-2.20 (m, 4H), 2.40 (br, s, 2H), 3.32-3.35 (d, 2H), 3.82-3.84 (m, 2H), 3.91-3.96 (t, 1H, J=7.8 Hz), 4.13-4.20 (q, 2H, J=7.5 Hz), 4.58 (br s, 2H), 5.25-5.27 (d, 1H, J=8.1 Hz), 5.89 (d, 1H, J=15.3 Hz), 6.32 (br, s, 1H), 6.81 (dd, 1H, J=15.6 Hz, 5.1 Hz), 6.92 (m, 1H), 7.77 (m, 1H).
- ESI-MS (M+H+)=539.
- Compound 21 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.92-0.96 (m, 12H), 1.27 (t, 3H, J=7.2), 1.43 (s, 9H), 2.04-2.11 (m, 2H), 2.38 (s, br, 2H), 3.23-3.35 (m, 2H), 3.83 (t, 1H, J=7.2), 4.16 (q, 2H, J=7.2), 4.61 (m, 2H), 5.00-5.03 (m, 1H), 5.89 (d, 1H, J=15.3), 6.48 (s, br, 1H), 6.81 (dd, 1H, J=15.6, 5.1), 7.00 (m, 1H), 7.68 (m, 1H).
- ESI-MS (M+H+)=539.
- Compound 22 was prepared in a manner similar to that described, in Example 1.
- 1H NMR (CDCl3) δ 0.91 (s, br, 12H), 1.21-1.25 (m, 4H), 1.34-1.36 (m, 1H), 1.51-1.75 (m, 1H), 2.00-2.13 (m, 2H), 2.34 (m, 2H), 3.26-3.29 (m, 2H), 3.64 (s, br, 2H), 3.94-3.96 (m, 1H), 4.15 (q, 2H, J=6.9), 4.22 (m, 2H), 4.54 (s, 2H), 4.59 (s, br, 1H), 5.45 (d, 1H, J=7.5), 5.89 (d, 1H, J=15.6), 6.61 (s, br, 1H), 6.80 (dd, 1H, J=15.9, 4.5), 7.01 (d, 1H, J=7.2), 7.30 (m, 5H), 7.74 (d, 1H, J=7.2).
- ESI-MS (M+H+)=616.
- Compound 23 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=545.
- Compound 24 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=558.
- Compound 25 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CD3OD) δ 0.95-1.00 (m, 12H), 1.26-1.29 (m, 6H), 1.57-1.85 (m, 5H), 2.03-2.14 (m, 3H), 2.27-2.32 (m, 1H), 2.45-2.52 (m, 1H), 3.93 (s, br, 2H), 4.03-4.04 (m, 1H), 4.16-4.20 (m, 5H), 4.37-4.41 (m, 1H), 4.59-4.63 (m, 1H), 5.94 (d, 1H, J=15.6), 6.89 (dd, 1H, J=15.6, 4.5).
- ESI-MS (M+H+)=568.
- Compound 26 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.86-0.96 (m, 12H), 1.27 (t, 3H, J=6.9), 1.49-1.82 (m, 10H), 1.95-2.02 (m, 1H), 2.40 (s, br, 2H), 3.32-3.34 (m, 2H), 4.16 (q, 2H, J=6.9), 4.55-4.67 (m, 3H), 5.89 (d, 1H, J=15.3), 6.39 (s, br, 1H), 6.72 (d, 1H, J=5.4), 6.81 (dd, 2H, J=15.9, 5.1), 7.31-7.76 (m, 5H).
- ESI-MS (M+H+)=557.
- Compound 27 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=690.
- Compound 28 was prepared in a manner similar to that, described in Example 1.
- 1H NMR (CDCl3) δ 0.89-0.94 (m, 6H), 1.22-1.28 (m, 5H), 1.57-2.03 (m, 8H), 2.43 (m, 2H), 3.33 (d, 2H, J=6.6), 3.65 (s, 3H), 3.67 (s, 3H) 4.15 (q, 2H, J=6.9), 4.26 (m, 1H), 4.44 (m, 1H), 4.60 (m, 1H), 5.28 (s, 1H), 5.91 (d, 1H, J=15.6), 6.24-6.29 (m, 1H), 6.82 (dd, 1H, J=15.9, 5.4), 7.89 (m, 1H).
- ESI-MS (M+H+)=542.
- Compound 29 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 7.78 (d, J=7.5 Hz, 1H), 7.28 (s, 5H), 7.01 (d, J=7.5 Hz, 1H), 6.79 (dd, J=15.5, 5.5 Hz, 1H), 6.50 (s, 1H), 5.89 (d, J=15.5 Hz, 1H), 5.38 (d, J=7.0 Hz, 1H), 4.46-4.61 (m, 4H), 4.06-4.21 (m, 4H), 3.29 (d, J=9.0 Hz, 2H), 2.35 (br, s, 2H), 2.03 (s, 3H), 1.47-1.72 (m, 3H), 1.44 (s, 9H), 1.17-1.28 (m, 6H), 0.88 (d, J=8.4 Hz, 3H), 0.86 (d, J=8.4 Hz 3H).
- ESI-MS (M+H+)=631.
- Compound 30 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=663.
- Compound 31 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.84-0.94 (m, 6H), 1.07 (m, 3H), 1.25 (m, 3H), 1.27 (s, 9H), 1.44 (s, 9H), 1.66-1.73 (m, 5H), 2.37 (br, s, 1H), 3.33 (d, 2H, J=8.1), 4.08-4.19 (m, 5H), 4.42-4.58 (m, 2H), 5.53-5.16 (d, 1H, J=4.8 Hz), 5.87-5.92 (d, 1H, J=15.6 Hz), 6.77-6.84 (dd, 1H, J=15.3 Hz, 5.1 Hz), 7.34-7.37 (d, 1H, J=8.1 Hz), 7.650-7.60 (m, 1H).
- ESI-MS (M+H+)=597.
- Compound 32 was prepared in a manner similar to that described, in Example 1.
- ESI-MS (M+H+)=561.
- Compound 33 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.83-0.88 (m, 6H), 1.10-1.20 (m, 9H), 1.30-1.35 (t, 2H, J=7.5), 1.57-1.96 (m, 5H), 2.38 (s, br, 2H), 3.02-3.09 (q, 1H, J=7.8), 3.27-3.39 (m, 4H), 4.10 (q, 2H, J=6.9), 4.34 (s, br, 2H), 4.50 (m, 1H), 4.60 (m, 1H), 4.95 (s, br, 1H), 5.80-5.85 (d, 1H, J=15.6), 6.25 (s, br, 1H), 6.73 (dd, 1H, J=4.5), 7.31 (s, br, 1H), 7.69 (s, br, 1H).
- ESI-MS (M+H+)=527.
- Compound 34 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.93 (s, br, 6H), 1.28 (t, 3H, J=6.9), 1.60-2.00 (m, 9H), 2.29 (m, 1H), 2.49 (m, 1H), 3.21-3.34 (m, 4H), 3.65-3.69 (m, 6H), 4.17 (q, 2H, J=6.6), 4.30 (m, 1H), 4.50 (m, 1H), 4.78 (m, 1H), 5.14 (m, 1H), 5.87 (d, 1H, J=15), 6.49-6.56 (m, 1H), 6.80-6.86 (m, 2H).
- ESI-MS (M+H+)=570.
- Compound 35 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.94 (dd, 6H, J=12, 4.8), 1.29 (t, 3H, J=6.9), 1.67-2.04 (m, 9H), 2.30-2.50 (m, 2H), 2.94 (s, 3H), 2.96 (s, 3H), 3.18 (s, br, 2H), 3.35 (s, br, 2H), 4.05 (m, 1H), 4.18 (q, 2H, J=6.9), 4.49-4.52 (m, 1H), 4.61-4.77 (m, 1H), 5.30 (s, 1H), 5.90 (d, 1H, J=15.6), 6.25-6.34 (m, 1H), 6.82 (m, 1H), 7.38 (m, 1H), 7.77 (d, 1H, J=7.5).
- ESI-MS (M+H+)=610.
- Compound 36 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.838 (m, 12H), 1.18 (t, 3H, J=6.3), 1.44-1.68 (m, 5H), 2.04-2.10 (m, 3H), 2.28 (m, 2H), 3.20-3.23 (m, 2H), 3.90-3.95 (m, 1H), 4.07-4.10 (m, 2H), 4.54 (s, br, 1H), 5.01 (s, 2H), 5.52-5.55 (m, 1H), 5.84 (d, 1H, J=15.6), 6.63 (s, 1H), 6.75 (dd, 1H, J=15.6, J=4.8), 7.73 (d, 1H, J=6.9).
- ESI-MS (M+H+)=573.
- Compound 37 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.89 (m, 6H), 1.23 (t, 3H, J=10.2), 1.45-1.99 (m, 6H), 2.36-2.58 (m, 2H), 2.94-3.09 (m, 2H), 3.26-3.34 (m, 2H), 4.10-4.20 (m, 3H), 4.44-4.54 (m, 2H), 5.04 (s, 2H), 5.89 (d, 1H, J=15.3), 6.79 (dd, 1H, J=15.3, 4.8), 7.16-7.30 (m, 10H).
- ESI-MS (M+H+)=621.
- Compound 38 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CD3OD) δ 0.79-0.91 (m, 6H), 1.20-1.28 (m, 3H), 1.45-1.83 (m, 6H), 2.32-2.53 (m, 2H), 2.92-3.24 (m, 4H), 4.10-4.20 (m, 2H), 4.41-4.58 (m, 3H), 5.13 (s, 2H), 5.91 (dd, 1H, J=15.6, 1.5), 6.77-6.91 (m, 3H), 7.18-7.32 (m, 7H).
- ESI-MS (M+H+)=637.
- Compound 39 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CD3OD) δ 0.79-0.91 (m, 6H), 1.20-1.28 (m, 3H), 1.45-1.83 (m, 6H), 2.36-2.57 (m, 2H), 2.92-3.24 (m, 4H), 4.10-4.20 (m, 2H), 4.41-4.58 (m, 3H), 5.13 (s, 2H), 5.91 (dd, 1H, J=15.6, 1.5), 6.82-6.91 (m, 3H), 7.21-7.35 (m, 7H).
- ESI-MS (M+H+)=639.
- Compound 40 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CD3OD) δ 0.79-0.90 (m, 6H), 1.20-1.29 (m, 3H), 1.45-1.83 (m, 6H), 2.36-2.57 (m, 2H), 2.94-3.10 (m, 2H), 3.26-3.34 (m, 2H), 4.10-4.20 (m, 2H), 4.44-4.61 (m, 3H), 5.10 (s, 2H), 5.90 (dd, 1H, J=15.6, 1.5), 6.83-6.94 (m, 4H), 7.24-7.32 (m, 5H).
- ESI-MS (M+H+) 657.
- Compound 41 was prepared in a manner similar to that, described in Example 1.
- 1H NMR (CDCl3) δ 0.79 (s, br, 6H), 1.12-1.22 (m, 7H), 1.38-1.96 (m, 3H), 2.32 (s, br, 1H), 2.90-3.05 (m, 2H), 3.21 (m, 2H), 4.10 (q, 2H, J=6.9), 4.37-4.58 (m, 3H), 4.95-5.02 (m, 3H), 5.85 (d, 1H, J=15.9), 6.17-6.18 (m, 2H), 6.70-6.77 (m, 2H), 7.03 (m, 1H), 7.25 (s, br, 5H), 7.54 (s, 1H), 8.16 (d, 1H, J=7.2).
- ESI-MS (M+H+)=610.
- Compound 42 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=711.
- Compound 43 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.69-0.83 (m, 6H), 1.21 (t, 3H, J=6.9), 1.29 (d, 1H, J=5.1), 1.44 (m, 1H), 1.86-2.23 (m, 6H), 2.97-2.99 (m, 2H), 3.13-3.21 (m, 2H), 3.88 (s, 1H), 4.09 (q, 2H, J=6.9), 4.43 (m, 1H), 4.71-4.77 (m, 1H), 5.02 (s, 2H), 5.36-5.40 (m, 1H), 5.65 (d, 1H, J=15.9), 6.61 (dd, 1H, J=15.3, J=4.5), 7.08-7.26 (m, 10H), 7.46-7.49 (m, 1H).
- ESI-MS (M+H+)=607.
- Compound 44 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=579.
- Compound 45 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 7.83 (d, J=8 Hz, 1H), 7.28-7.36 (m, 5H), 6.81 (dd, J=16, 6 Hz, 1H), 6.47 (s, 1H), 5.91 (d, J=15 Hz, 1H), 5.53 (d, J=8 Hz, 1H), 5.07-5.13 (m, 2H), 4.60-4.68 (m, 2H), 4.13 (q, J=7 Hz, 2H), 3.97 (dd, J=8, 3.6 Hz, 1H), 3.28-3.31 (m, 2H), 2.49 (t, J=7 Hz, 2H), 2.29-2.42 (m, 2H), 1.90-2.21 (m, 6H), 2.06 (s, 3H), 1.76 (m, 1H), 1.60 (m, 1H), 1.26 (t, J=7 Hz, 3H), 0.94 (d, J=6.9 Hz, 3H) 0.91 (d, J=6.9 Hz, 3H).
- ESI-MS (M+H+)=591.
- Compound 46 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 7.75 (d, J=7.5 Hz, 1H), 7.50 (d, J=8.4 Hz, 1H), 7.24-7.52 (m, 5H), 6.82 (dd, J=15, 5 Hz, 1H), 6.54 (s, 1H), 5.89 (dd, J=15, 1.8 Hz, 1H), 5.42 (d, J=7 Hz, 1H), 5.02-5.12 (m, 2H), 4.60-4.67 (m, 2H), 4.13 (q, J=7.2 Hz, 2H), 3.28-3.30 (m, 2H), 2.49 (t, J=7.5 Hz, 2H), 2.33-2.43 (m, 2H), 1.90-2.14 (m, 6H), 2.06 (s, 3H), 1.46-1.79 (m, 3H), 1.26 (t, J=7.2 Hz, 3H) 0.92 (d, J=1.5 Hz, 6H).
- ESI-MS (M+H+)=605.
- Compound 47 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=639.
- Compound 48 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=546.
- Compound 49 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 1.26 (t, 3H, J=6.9), 1.55-1.63 (m, 1H), 1.75-1.82 (m, 1H), 1.94-2.02 (m, 1H), 2.22-2.31 (m, 1H), 2.41-2.51 (m, 1H), 3.59-3.60 (m, 1H), 3.68-3.73 (m, 1H), 3.82-3.87 (m, 2H), 4.15 (q, 2H, J=6.9), 4.27-4.29 (m, 1H), 4.44-4-50 (m, 1H), 4.63 (s, br, 1H), 5.10 (s, 2H), 5.95 (d, 1H, J=15.6), 6.85 (dd, 1H, J=15.6, 4.5), 7.2-7.34 (m, 4H), 8.16 (d, 1H, J=8.7).
- ESI-MS (M+H+)=571.
- Compound 50 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=594.
- Compound 51 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.88 (s, br, 6H), 1.18-1.77 (m, 12H), 2.38 (m, 1H), 2.93 (s, 3H), 2.97 (s, 3H), 3.29 (m, 2H), 4.10 (q, 2H, J=6.9), 4.49 (m, 2H), 5.15-5.21 (m, 1H), 5.37 (q, 1H, J=5.7), 5.80-5.85 (m, 2H), 6.07 (s, br, 1H), 6.73 (dd, 1H, J=15, 5.4), 7.29 (d, 1H, J=8.7), 7.82 (m, 1H), 8.70 (m, 1H).
- ESI-MS (M+H+)=596.
- Compound 52 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.83-0.87 (m, 6H), 1.14 (s, 6H), 1.16-1.20 (m, 6H), 1.42-1.67 (m, 6H), 2.22-2.26 (m, 2H), 3.32-4.10 (m, 4H), 4.47 (br, s, 2H), 5.80-5.85 (d, 1H, J=15.3 Hz), 6.70-6.77 (dd, 1H, J=15.3 Hz, 5.1 Hz), 7.79-7.87 (br, s, 2H).
- ESI-MS (M+H+)=497.
- Compound 53 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.96 (s, br, 6H), 1.16-1.30 (m, 15H), 1.62-2.02 (m, 6H), 2.33-2.46 (m, 2H), 2.98 (d, 3H, J=8.7), 3.34 (s, br, 2H), 3.88-3.91 (m, 1H), 4.14-4.19 (m, 3H), 4.40 (m, 1H), 4.60-4.76 (m, 1H), 5.76-6.14 (m, 3H), 6.81 (d, 1H, J=15), 7.60 (m, 1H).
- ESI-MS (M+H+)=575.
- Compound 54 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.97 (t, 6H, J=0.8), 1.08 (d, 3H, J=5.7), 1.28 (s, b, 12H), 1.55-1.86 (m, 6H), 2.05 (m, 1H), 2.42 (m, 2H), 3.31 (d, 2H, J=8.1), 4.14-4.25 (m, 5H), 4.37-4.45 (m, 3H), 4.60 (m, 1H), 5.91-6.10 (m, 3H), 6.83 (dd, 1H, J=15.6, 4.5), 7.26-7.76 (m, 9H).
- ESI-MS (M+H+)=719.
- Compound 55 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.96-0.99 (m, 6H), 1.14 (d, 3H, J=6.6), 1.24 (s, 9H), 1.28 (t, 3H, J=6.9), 1.39 (t, 3H, J=6.9), 1.58-2.04 (m, 5H), 2.35-2.40 (m, 2H), 3.05 (q, 2H, J=7.5), 3.31-3.34 (m, 2H), 3.87-3.89 (m, 1H), 4.09-4.10 (m, 1H), 4.17 (q, 2H, J=7.2), 4.41 (m, 1H), 4.59 (m, 1H), 4.74 (m, 1H), 5.73 (d, 1H, J=6.0), 5.84-5.96 (m, 1H), 6.22 (s, 1H), 6.41 (q, 1H, J=15.9, 4.8), 7.57-7.60 (m, 1H), 7.69 (d, 1H, J=7.2).
- ESI-MS (M+H+)=589.
- Compound 56 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=603.
- Compound 57 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.85-0.90 (m, 6H), 1.27 (t, 3H, J=7.2 Hz), 1.60-1.66 (m, 5H), 2.33 (m, 1H), 2.79 (m, 1H), 2.94 (m, 1H), 3.20 (m, 2H), 4.17 (q, 2H, J=6.9 Hz), 4.39 (m, 1H), 4.55 (m, 2H), 5.10 (s, 2H), 5.91 (d, 1H, J=15.9 Hz), 6.40 (m, 1H), 6.85 (dd, 1H, J=15.9, 5.1 Hz), 7.31 (m, 20H), 7.84 (m, 1H).
- ESI-MS (M+H+)=637.
- Compound 58 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.88-0.94 (m, 6H), 1.27 (t, 3H, J=7.2 Hz), 1.60-1.66 (m, 5H), 2.07 (m, 1H), 2.43 (m, 2H), 2.72-2.80 (m, 2H), 3.30 (m, 2H), 4.17 (q, 2H, J=6.9 Hz), 4.39 (m, 1H), 4.55 (m, 2H), 5.10 (s, 2H), 5.91 (d, 1H, J=15.9 Hz), 6.10-6.20 (m, 2H), 6.30 (m, 2H), 6.85 (dd, 1H, J=15.9, 5.1 Hz), 7.31 (m, 5H), 7.60 (m, 1H).
- ESI-MS (M+H+)=588.
- Compound 59 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CD3OD) δ 0.86-1.04 (m, 6H), 1.21-1.52 (m, 12H), 1.61-1.71 (m, 6H), 2.06-2.86 (m, 6H), 3.40 (m, 2H), 4.10-4.27 (m, 2H),4.34-4.45 (m, 1H), 4.60-4.72 (m, 1H), 5.13 (s, 2H), 5.90 (d, 1H, J=15.6), 6.81 (dd, 1H, J=15.6, 4.8), 7.27-7.54 (m, 5H).
- ESI-MS (M+H+)=645.
- Compound 60 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CD3OD) δ 0.92-1.00 (m, 6H), 1.19-1.23 (m, 6H), 1.57-1.80 (m, 6H), 2.03-2.36 (m, 4H), 3.19-3.31 (m, 2H), 4.16-4.34 (m, 4H), 4.58-4.62 (m, 1H), 5.04-5.11 (m, 2H), 5.24 (d, 1H, J=5.1), 5.91 (d, 1H, J=15.3), 6.89 (dd, 1H, J=15.3, 5.4), 7.30-7.35 (m, 5H).
- ESI-MS (M+H+)=576.
- Compound 61 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=576.
- Compound 62 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=617.
- Compound 63 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+Na+)=867.
- Compound 64 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.94-0.99 (m, 6H), 1.07 (m, 3H), 1.28 (m, 15H), 1.60 (m, 3H), 2.10 (br, s, 2H), 2.29 (br, s, 2H), 3.32-3.35 (d, 2H), 4.09 (m, 6H), 4.32 (br, s, 1H), 4.60 (br, s, 1H), 5.76 (m, 1H), 5.84-5.89 (d, 1H, J=14.7 Hz), 5.98 (br, s, 1H), 6.81 (dd, 1H, J=15.9 Hz, 5.4 Hz), 7.38 (m, 1H), 7.60 (m, 1H).
- ESI-MS (M+H+)=569.
- Compound 65 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.94-0.99 (m, 6H), 1.28 (t, 3H, J=6.9), 1.75-1.82 (m, 2H), 2.10-2.33 (m, 3H), 3.03-3.15 (m, 2H), 3.22-3.31 (m, 2H), 4.16 (q, 2H, J=7.5), 4.39-4.51 (m, 2H), 4.80-4.83 (m, 1H), 5.77 (d, 1H, J=15.6), 5.96 (s, 1H), 6.66-6.74 (m, 2H), 7.15-7.62 (m, 10H), 7.7 (d, 2H, J=8.1).
- ESI-MS (M+H+)=577.
- Compound 66 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=630.
- Compound 67 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.91 (s, br, 6H), 1.26 (t, 3H, J=6.9), 1.42 (s, 18H), 1.56-1.63 (m, 5H), 1.80-1.82 (m, 2H), 2.04 (m, 1H), 2.35-2.41 (m, 3H), 3.12 (s, br, 2H), 3.32 (s, br, 2H), 4.16 (m, 3H), 4.54 (s, br, 2H), 5.89 (d, 1H, J=15.6), 6.81 (m, 2H).
- ESI-MS (M+H+)=654.
- Compound 68 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=809.
- Compound 69 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=557.
- Compound 70 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=547.
- Compound 71 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=562.
- Compound 72 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=605.
- Compound 73 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=600.
- Compound 74 was prepared in a manner similar to that, described in Example 1.
- 1H NMR (CDCl3) δ 0.88-0.98 (m, 6H), 1.19-1.86 (m, 15H), 2.0-2.08 (m, 1H), 2.15-2.39 (m, 2H), 2.47-2.59 (m, 1H), 2.94 (m, 2H), 3.98-4.20 (m, 3H), 4.30-4.36 (m, 1H), 4.60-4.64 (m, 1H), 5.09 (m, 2H), 5.89 (d, 1H, J=15.6), 6.89 (dd, 1H, 15.6, 4.8), 7.26-7.33 (m, 5H).
- ESI-MS (M+H+)=602.
- Compound 75 was prepared in a manner similar to that, described in Example 1.
- 1H NMR (CDCl3) δ 0.89-0.93 (m, 6H), 1.13-1.15 (m, 3H), 1.22-1.27 (m, 3H), 1.55-1.76 (m, 4H), 1.95-2.-2 (m, 1H), 2.03-2.46 (m, 2H), 3.28-3.30 (m, 2H), 4.11-4.18 (m, 3H), 4.33 (br s, 1H), 4.54-4.56 (br s, 2H), 5.07 (s, 2H), 5.84-5.94 (d, 1H, J=15.9 Hz), 6.03-6.06 (d, J=7.2 Hz), 6.76-6.83 (dd, 1H, J=15.0 Hz, 5.4 Hz), 7.31 (br s, 5H), 8.02 (br s, 1H).
- ESI-MS (M+H+)=575.
- Compound 76 was prepared as follows: Compound 74 (0.047 g, 0.11 mmol) was dissolved in CH2Cl2 (1.5 ml). Et3N (0.037 ml, 3.0 eq.) was then added to the above solution. The resultant solution was stirred at room temperature for 30 minutes. Methyl chloroformate (0.013 ml, 1.5 eq.) was subsequently added. The reaction mixture was stirred at room temperature for another 20 hours and then concentrated to afford a residue. The residue was purified by flash column chromatography (5% MeOH in CH2Cl2) to afford compound 76 as a white solid (64 mg, 85%).
- 1H NMR (CDCl3) δ 0.88-0.98 (m, 6H), 1.19-1.83 (m, 15H), 2.0-2.08 (m, 1H), 2.15-2.38 (m, 2H), 2.47-2.59 (m, 1H), 3.07 (m, 2H), 3.59 (s, 3H), 3.98-4.20 (m, 3H), 4.310-4.36 (m, 1H), 4.60-4.64 (m, 1H), 5.08 (m, 2H), 5.88 (d, 1H, J=15.6), 6.89 (dd, 1H, 15.6, 4.8), 7.27-7.32 (m, 5H).
- ESI-MS (M+H+)=660.
- Compound 77 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=523.
- Compound 78 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=557.
- Compound 79 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=423.
- Compound 80 was prepared as follows: Compound 59 (0.023 g, 0.036 mmol) was added to a solution of HCl in 1,4-dioxane (4.0 M, 2 ml). The solution was stirred at room temperature for 30 minutes and then concentrated to give compound 80 as a white solid (21 mg, 99%);
- 1H NMR (CD3OD) δ 0.86-1.04 (m, 6H), 1.23 (s, br, 3H), 1.60-1.71 (m, 6H), 2.06-2.85 (m, 6H), 3.38 (m, 2H), 4.10-4.28 (m, 2H), 4.34-4.45 (m, 1H), 4.60-4.72 (m, 1H), 5.13 (s, 2H), 5.91 (d, 1H, J=15.9), 6.82 (dd, 1H, J=15.9, 4.7), 7.27-7.54 (m, 5H).
- ESI-MS (M+H+)=589.
- Compound 81 was prepared in 20% yield from compound 52 and methyl chloroformate.
- 1H NMR (CDCl3) δ 0.94-0.99 (m, 6H), 1.07 (m, 3H), 1.28 (m, 12H), 1.60 (m, 3H), 2.10 (br s, 2H), 2.29 (br s, 2H), 3.32-3.35 (d, 2H), 3.69 (s, 3H), 4.18 (m, 4H), 4.39 (br s, 1H), 4.61 (br s, 1H), 5.59-5.81 (m, 2H), 5.89-5.95 (d, 1H, J=16.2 Hz), 6.82 (dd, 1H, J=15.3 Hz, 5.7 Hz), 7.34 (m, 1H), 7.56 (m, 1H).
- ESI-MS (M+H+)=555.
- Compound 82 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.95 (m, 6H), 1.02-1.04 (m, 3H), 1.27 (s, 12H), 1.56-1.82 (m, 5H), 2.03 (s, 3H), 2.18 (m, 1H), 2.40 (m, 2H), 3.31-3.34 (m, 2H), 4.15-4.18 (m, 3H), 4.36 (m, 1H), 4.46 (m, 1H), 4.61 (m, 1H), 5.92 (d, 1H, J=15 Hz), 6.38 (s, 1H), 6.63 (s, 1H), 6.82 (d, 1H, J=15 Hz), 7.53 (d, 1H, J=6 Hz), 7.65 (d, 1H, J=6 Hz).
- ESI-MS (M+H1)=539.
- Compound 83 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.96 (t, 6H, J=6 Hz), 1.08 (d, 3H, J=6 Hz), 1.26 (s, 9H), 1.54-2.42 (m, 8H), 3.35 (d, 2H, J=9 Hz), 3.68 (t, 2H, J=6 Hz), 4.14-4.18 (m, 4H), 4.27-4.38 (m, 2H), 4.45 (br, 1H), 4.60 (br, 1H), 5.92 (d, 2H, J=15 Hz), 6.32 (s, 1H), 6.83 (dd, 1H, J=15.0 Hz, 6.0 Hz), 7.39 (d, 1H, J=6 Hz), 7.66 (d, 1H, J=6 Hz).
- ESI-MS (M+Na+)=625.
- Compound 84 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.97 (q, 6H, J=6 Hz), 1.13 (d, 3H, J=6 Hz), 1.26 (s, 12H), 1.55-2.06 (m, 6H), 2.41 (br, 2H), 3.32 (d, 2H, J=9 Hz), 4.04-4.09 (m, 2H), 4.18 (q, 2H, J=6 Hz), 4.41 (br, 1H), 4.59 (br, 1H), 5.93 (d, 1H, J=15 Hz), 6.32 (s, 1H), 6.83 (dd, 1H, J=15.0 Hz, 6.0 Hz), 7.02 (d, 1H, J=6 Hz), 7.58 (d, 1H, J=6 Hz), 7.79 (d, 1H, J=6 Hz).
- ESI-MS (M+H+)=629.
- Compound 85 was prepared in a manner similar to that described in Example 1 in a 68% yield.
- 1H NMR (CDCl3) δ 7.83 (d, J=8 Hz, 1H), 7.28-7.36 (m, 5H), 6.81 (dd, J=16, 6 Hz, 1H), 6.47 (s, 1H), 5.91 (d, J=15 Hz, 1H), 5.53 (d, J=8 Hz, 1H), 5.07-5.13 (m, 2H), 4.60-4.68 (m, 2H), 4.13 (m, 3H), 3.97 (dd, J=8, 3.6 Hz, 1H), 3.28-3.31 (m, 2H), 2.49 (t, J=7 Hz, 2H), 2.29-2.42 (m, 2H), 1.90-2.21 (m, 6H), 2.06 (s, 3H), 1.76 (m, 1H), 1.26 (m, 12H), 0.95 (d, J=6.9 Hz, 3H).
- ESI-MS (M+H+)=649.
- Compound 86 was prepared in a manner similar to that described in Example 1 in a 57% yield.
- 1H NMR (CDCl3) δ 7.83 (d, J=8 Hz, 1H), 7.28-7.36 (m, 5H), 6.81 (dd, J=16, 6 Hz, 1H), 6.47 (s, 1H), 5.91 (d, J=15 Hz, 1H), 5.53 (d, J=8 Hz, 1H), 5.07-5.13 (m, 2H), 4.60-4.68 (m, 2H), 4.13 (q, J=7 Hz, 2H), 3.97 (dd, J=8, 3.6 Hz, 1H), 3.28-3.31 (m, 2H), 2.06-2.86 (m, 6H), 1.90-2.21 (m, 6H), 2.06 (s, 3H), 1.76 (m, 1H), 1.21-1.52 (m, 12H).
- ESI-MS (M+H+)=663.
- Compound 87 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.98 (d, 6H, J=6 Hz), 1.09 (s, 12H), 1.27 (t, 3H, J=6 Hz), 1.50-2.49 (m, 8H), 3.32 (q, 2H, J=3 Hz), 3.63 (q, 1H, J=3 Hz), 3.87-3.90 (m, 1H), 4.16 (q, 2H, J=6 Hz), 4.29-4.45 (m, 1H), 4.77 (m, 1H), 5.84 (br, 1H), 5.93 (d, 1H, J=15 Hz), 6.12 (d, 1H, J=6 Hz), 6.81 (dd, 1H, J=15.0 Hz, 6.0 Hz), 7.33-7.44 (m, 5H), 8.48 (d, 1H, J=9 Hz).
- ESI-MS (M+H+)=651.
- Compound 88 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.91-0.96 (m, 6H), 1.04-1.06 (m, 3H), 1.23 (m, 12H), 1.51-2.05 (m, 8H), 2.40 (br s, 2H), 3.30 (m, 2H), 4.15 (m, 4H), 4.39 (m, 1H), 4.54 (m, 2H), 5.19-5.32 (m, 2H), 5.84-5.97 (m, 3H), 6.82 (dd, 1H, J=15.6 Hz, 5.4 Hz), 7.35 (m, 1H), 7.60 (m, 1H).
- ESI-MS (M+H+)=581.
- Compound 89 was prepared in a 85% yield by reacting compound 1 with pivaloyl chloride in the presence of Et3N and DMAP.
- 1H NMR (CDCl3) δ 0.94-0.98 (m, 6H), 1.08 (d, J=6.3 Hz, 3H), 1.25 (s, 9H), 1.66-1.73 (m, 5H), 2.21-2.50 (m, 2H), 3.20-3.30 (m, 2H), 4.16 (q, J=6.9 Hz, 2H), 4.42 (br, 1H), 4.58 (br, 1H), 5.10 (s, 2H), 5.9 (d, J=15.6 Hz, 1H), 6.82 (dd, J=15.3 Hz, 5.1 Hz, 1H), 7.2-7.34 (m, 4H), 7.60 (d, J=7.5 Hz, 1H).
- ESI-MS (M+H+)=659.
- Compound 6 was dissolved in an 1N NaOH/EtOH solution. The mixture was stirred for 1 hour and concentrated to afford a residue. The residue was purified by column chromatography to give compound 90 in a 20% yield.
- 1H NMR (CDCl3) δ 0.83-0.93 (m, 6H), 1.02-1.04 (d, 4H, J=5.7 Hz), 1.16-1.31 (m, 11H), 1.52-1.74 (m, 5H), 2.0 (m, 1H), 2.30-2.43 (m, 2H), 3.24-3.26 (m, 2H), 4.15 (m, 2H), 4.41 (br s, 1H), 4.63 (br s 1H), 5.08 (s, 2H), 5.9 (m, 1H), 6.82 (m, 1H) 7.29-7.33 (m, 5H), 7.47 (d, 1H, J=8.1 Hz), 7.69 (m, 1H).
- ESI-MS (M+H+)=603.
- Compound 91 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.93 (q, 6H, J=3 Hz), 1.05 (d, 3H, J=6 Hz), 1.21-1.24 (m, 15H), 1.42-2.05 (m, 6H), 2.38 (br, 2H) 3.26-3.29 (m, 2H), 4.15 (br, 2H), 4.39 (m, 1H), 4.57 (m, 1H), 4.97-5.14 (m, 3H), 5.85-5.90 (m, 3H), 6.78 (dd, 1H, J=15.6 Hz, 5.4 Hz), 7.34 (m, 5H), 7.57 (d, 1H, J=7.2 Hz).
- ESI-MS (M+H+)=645.
- Compound 92 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.93-0.98 (m, 6H), 1.10 (d, 3H, J=6.3), 1.25 (s, 9H), 1.55-1.68 (m, 9H), 2.40 (m, 3H), 3.30-3.39 (m, 2H), 4.10-4.20 (m, 4H), 4.26-4.36 (m, 1H), 4.25-4.58 (m, 1H), 5.10 (q, 2H, J=12), 5.49 (d, 1H, J=16.5), 5.64 (s, 1H), 5.84 (d, 1H, J=5.4), 6.59 (dd, J16.5, 5.0H), 7.29-7.34 (m, 5H), 7.96 (d, J=6.0).
- ESI-MS (M+H+)=584.1.
- Compound 93 was prepared in a manner similar to that described in Example 1 in a 66% yield.
- 1H NMR (CDCl3) δ 0.86-095 (m, 6H), 1.22 (m, 4H), 1.41 (m, 11H), 1.55-1.90 (m, 9H), 2.32 (m, 2H), 3.25-3.35 (m, 3H), 3.39 (m, 1H), 4.11-4.19 (m, 2H), 4.34-4.47 (m, 2H), 4.85 (m, 1H), 5.08 (s, 2H), 5.84 (m, 2H), 6.09 (m, 1H), 6.73-6.75 (m, 1H), 7.73 (m, 1H).
- ESI-MS (M+H+)=707
- Compound 94 was prepared as follows: Compound 93 was added into a solution of HCl in 1,4-dioxane. The mixture was stirred at room temperature for 30 minutes and concentrated. CH2Cl2 was then added to the resultant residue and the mixture was cooled down to 0-5° C. N-methylmorpholine was added into the mixture, which was then stirred for 10 minutes. Benzochloromate was subsequently added to the solution, which was stirred at room temperature for another 2 hours to give a crude product. The crude product was purified by flash column chromatography to give compound 94.
- 1H NMR (CDCl3) δ 0.93-0.98 (m, 6H), 1.22 (m, 4H), 1.41 (m, 11H), 1.55-1.90 (m, 9H), 2.32 (m, 2H), 3.25-3.35 (m, 3H), 3.39 (m, 1H), 4.11-4.19 (m, 2H), 4.34-4.47 (m, 2H), 4.85 (m, 1H), 5.84 (m, 2H), 6.09 (m, 1H), 6.73-6.75 (m, 1H), 7.73 (m, 5H).
- ESI-MS (M+H)− 585.
- Compound 95 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.93-0.98 (m, 6H), 1.07 (d, 3H, J=5.4), 1.27 (s, 9H), 1.52-2.10 (m, 8H), 2.40 (m, 2H), 3.23 (s, 3H), 3.28-3.31 (m, 2H), 3.68 (s, 3H), 4.16 (m, 2H), 4.44-4.45 (m, 1H), 4.63-4.64 (m, 1H), 5.10 (q, 2H, J=6), 5.90 (d, 1H, J=4.5), 6.51 (d, 1H, J=15.6), 6.83 (dd, 1H, J=5.1, J=15.3), 7.35 (m, 5H), 7.57-7.62 (m, 1H).
- ESI-MS (M+H+)=646.
- Compound 96 was prepared in a manner similar to that described in Example 1 in a 38% yield.
- 1H NMR (CDCl3) δ 0.95 (q, 6H, J=8.4 Hz), 1.09 (d, 3H, J=6.3 Hz), 1.17 (d, 6H, J=6.6 Hz), 1.26 (s, 9H), 1.52-1.82 (m, 5H), 1.99-2.06 (m, 1H), 2.38 (br, 2H), 3.27-3.30 (m, 2H), 4.06-4.21 (m, 3H), 4.41 (m, 1H), 4.61 (m, 1H), 5.11 (q, 2H, J=3 Hz), 5.65 (d, 1H, 1=7.8), 5.84-5.89 (m, 3H), 6.66 (dd, 1H, J=14.7 Hz, 5.4 Hz), 7.29-7.35 (m, 5H), 7.47 (d, 1H, J=7.8 Hz).
- ESI-MS (M+H+)=644.
- Compound 97 was prepared in a manner similar to that described in Example 1 in a 71% yield.
- 1H NMR (CDCl3) δ 0.25 (q, 2H, J=5.4 Hz), 0.50-0.56 (m, 2H), 0.93 (q, 6H, J=2.1 Hz), 1.03-1.18 (m, 4H), 1.24 (s, 9H), 1.50-2.07 (m, 7H), 2.36-2.41 (m, 2H), 3.25-3.28 (m, 2H), 3.92 (d, 2H, J=7.2 Hz), 4.14-4.16 (m, 2H), 4.40-4.45 (m, 1H), 4.58 (m, 1H), 5.08 (q, 2H, J=6.6 Hz), 5.87 (d, 1H, J=5.1 Hz), 5.93 (d, 1H, J=1.56 Hz), 6.08 (s, 1H), 6.82 (dd, 1H, J=15.9 Hz, 5.4 Hz), 7.29-7.38 (m, 5H), 7.63 (d, 1H, J=7.5 Hz).
- ESI-MS (M+Na+)=679.
- Compound 98 was prepared in a manner similar to that described in Example 1 in a 50% yield.
- 1H NMR (CDCl3) δ 0.85-098 (m, 6H), 1.06 (m, 4H), 1.26 (s, 9H), 1.44-1.63 (m, 9H), 1.75-1.80 (m, 7H), 2.05-2.34 (m, 2H), 3.27-3.29 (m, 2H), 3.70-3.72 (m, 1H), 4.14 (m, 2H), 4.42 (m, 1H), 4.59 (m, 1H), 5.08 (s, 2H), 5.88-5.98 (m, 4H), 6.09 (m, 1H), 6.80-6.87 (m, 1H), 7.25 (m, 10H), 7.65 (m, 1H).
- ESI-MS (M+H+)=707.
- Compound 99 was prepared by the procedures described follows;
- 8 ml of a 1 N LiOH aqueous solution at 0° C. was added to Intermediate 6 described in Example 1 (0.107 g, 0.243 mmol, 1 eq.) in THF (11 ml). The mixture was stirred at this temperature for 5 minutes, and then at room temperature for 1 hour. The reaction mixture was then partitioned between H2O (10 ml) and EtOAc (10 ml). The aqueous layer was acidified to pH=2 with a 10% KHSO4 aqueous solution and was extracted with EtOAc (2×10 ml). The organic layers were combined, dried over Na2SO4, and concentrated under vacuum to afford a crude corresponding carboxylic acid. Under an atmosphere of nitrogen, the carboxylic acid (0.100 g, 0.243 mmol, 1 eq.) was dissolved slowly in anhydrous DMF (1.2 ml, 0.2 M). After cesium carbonate (0.119 g, 0.365 mmol, 1.5 eq.) and benzyl bromide (0.062 g, 0.040 ml, 0.365 mmol, 1.5 eq.) were sequentially added into the above solution, the reaction mixture was stirred at ambient temperature overnight under N2. The reaction was then quenched by addition of a 10% KHSO4 aqueous solution (5 ml) slowly. The resultant solution was extracted with CH2Cl2 (5 ml×4). The organic layers were combined, washed with brine, dried over Na2SO4, and concentrated under vacuum to give a crude product. The crude product thus obtained was purified by flash chromatography (2% MeOH in CH2Cl2) on silica gel to afford intermediate 8 (94 mg, 77%) as a white solid. 1H NMR (CDCl3) δ 0.85 (d, J=4.8 Hz, 6H), 1.19 (m, 1H), 1.32 (s, 9H), 1.38-1.71 (m, 4H), 1.95-2.08 (m, 2H), 2.25-2.30 (m, 2H), 3.19-3.27 (m, 2H), 4.15 (m, 1H), 4.51 (m, 1H), 5.08 (s, 2H), 5.88 (d, J=15.3 Hz, 1H), 6.57 (br s, 1H), 6.79 (dd, J=15.3, 4.8 Hz, 1H), 7.24 (m, 5H), 7.55 (d, J=7.5 Hz, 1H). ESI-MS (M+H+)=502.
- A 4.0 M solution of HCl in 1,4-dioxane (1.78 ml) was added to a solution of Intermediate 8 (0.094 g, 0.187 mmol, 1 eq.) in the same solvent (1.8 ml) at 23° C. After 2 hours of stirring, the reaction mixture was concentrated under reduced pressure. The residue thus obtained was dissolved in CH2Cl2 (15 ml). Z-Thr(t-Bu)-OH (0.058 g, 0.187 mmol, 1.0 eq.), 4-methylmorpholine (0.080 ml, 0.750 mmol, 4.0 eq.), HOBt (0.038 g, 0.281 mmol, 1.5 eq.), and EDC (0.054 g, 0.281 mmol, 1.5 eq.) were added sequentially. The resultant solution was stirred overnight at 23° C. and then the solvent was removed under vacuum. The residue was partitioned between a 10% KHSO4 aqueous solution (1 ml) and CH2Cl2 (7 ml). The organic layer was dried over MgSO4, filtered, and concentrated. The crude product thus obtained was purified by flash chromatography (70% EtOAc in hexanes) to afford compound 99 (0.117 g, 90%) as a white foam. 1H NMR (CDCl3) δ 0.94 (dd, J=8.4, 6.0 Hz, 6H), 1.05 (d, J=6.3 Hz, 3H), 1.25 (s, 9H), 1.46-1.80 (m, 6H), 1.99-2.06 (m, 1H), 2.38 (m, 1H), 3.27-3.30 (m, 2H), 4.15 (m, 2H), 4.40 (m, 1H), 4.58 (m, 1H), 5.04-5.15 (m, 4H), 5.87 (s, 2H), 5.96 (dd, J=15.9, 1.2 Hz, 1H), 6.86 (dd, 1=15.6, 5, 4 Hz, 1H), 7.28-7.33 (m, 10H), 7.61 (d, J=7.2 Hz, 1H). ESI-MS (M+H+)=693.
- Compound 100 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.90-096 (m, 6H), 1.02-1.04 (m, 3H), 1.24 (s, 9H), 1.49-1.69 (m, 9H), 1.75-1.80 (m, 7H), 1.98-2.07 (m, 1H), 2.36 (m, 2H), 3.25-3.28 (m, 2H), 4.14 (m, 1H), 4.41 (m, 1H), 4.56 (m, 1H), 5.08 (s, 2H), 5.14-5.19 (m, 1H), 5.85-5.90 (m, 2H), 6.73-6.80 (m, 1H), 7.33 (m, 5H), 7.62 (m, 1H).
- ESI-MS (M+H+)=671.
- Compound 101 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 1.07 (d, J=6.3 Hz, 3H), 1.28 (s, 9H), 1.66-1.73 (m, 4H), 2.21-2.50 (m, 8H), 2.88 (m, 2H), 3.20-3.30 (m, 2H), 4.16 (q, J=6.9 Hz, 2H), 4.42 (br, 1H), 4.58 (br, 1H), 5.01-5.10 (m, 3H), 5.91 (d, J=15.6 Hz, 1H), 6.82 (dd, J=15.3 Hz, 5.1 Hz, 1H), 7.2-7.34 (m, 4H), 7.60 (d, J=7.5 Hz, 1H).
- ESI-MS (M+H+)=632.
- Compound 102 was prepared in a 66% yield by reacting compound 112 with
- (1.5 eq.) via a Wittig reaction for 24 hours.
- 1H NMR (CDCl3) δ 0.93-0.98 (m, 6H), 1.26 (s, 9H), 1.66-1.73 (m, 5H), 2.22-2.51 (m, 4H), 3.19-3.30 (m, 2H), 4.26 (t, J=6.9 Hz, 2H), 4.44 (br, 1H), 4.57 (br, 1H), 5.12 (s, 2H), 6.82 (d, J=5.1 Hz, 1H), 7.22-7.34 (m, 4H), 7.60 (d, J=7.5 Hz, 1H).
- ESI-MS (M+H+)=629.
- Compound 103 was prepared in a manner similar to that described in Example 1 in a 63% yield.
- 1H NMR (CDCl3) δ 0.94-0.98 (m, 6H), 1.06 (d, 3H, J=5.7 Hz), 1.27 (s, 9H), 1.53-2.10 (m, 6H), 2.38-2.43 (m, 2H), 3.28-3.30 (m, 2H), 3.72 (s, 3H), 4.16 (br, 2H), 4.48 (m, 1H), 4.59 (m, 1H), 5.11 (q, 2H, J=6.6 Hz), 5.93 (d, 2H, J=15.9 Hz), 6.12 (br, 1H), 6.84 (dd, 1H, J=15.6 Hz, 5.1 Hz), 7.35-7.39 (m, 5H), 7.65 (d, 1H, J=6.9 Hz).
- ESI-MS (M+H+)=617.
- Compound 104 was prepared in a manner similar to that described in Example 1 in a 35% yield.
- 1H NMR (CDCl3) δ 0.93-0.98 (m, 12H), 1.06 (d, 4H, J=5.7 Hz), 1.27 (s, 9H), 1.53-2.16 (m, 7H), 2.39-2.43 (m, 2H), 3.28-3.34 (m, 2H), 3.90 (d, 2H, J 6.9 Hz), 4.16-4.18 (m, 2H), 4.47-4.49 (m, 1H), 4.60 (br, 1H), 5.11 (q, 2H, J=6.9 Hz), 5.89 (d, 1H, J=5.4 Hz), 5.94 (d, 1H, J=15.6 Hz), 6.08 (s, 1H), 6.83 (dd, 1H, J=15.6 Hz, 5.1 Hz), 7.31-7.40 (m, 5H), 7.63 (d, 1H, J=7.5 Hz).
- ESI-MS (M+H+)=659.
- Compound 105 was prepared in a manner similar to that described in Example 1 in a 79% yield.
- 1H NMR (CDCl3) δ 0.93-0.98 (m, 6H), 1.05 (d, 3H, J=5.4 Hz), 1.26 (s, 9H), 1.53-2.11 (m, 7H), 2.37 (br, 2H), 3.28-3.33 (m, 2H), 4.16 (br, 2H), 4.50-4.52 (m, 2H), 4.62 (d, 2H, J=5.7 Hz), 5.10 (q, 2H, J=6.6 Hz), 5.23 (d, 1H, J=10.2 Hz), 5.31 (d, 1H, J=17.4 Hz), 5.85-5.98 (m, 3H), 6.86 (dd, 1H, J=15.6 Hz, 5.4 Hz), 7.35-7.41 (m, 5H), 7.69-7.74 (m, 1H).
- ESI-MS (M+H+)=643.
- Compound 106 was prepared in a manner similar to that described in Example 1 in a 92% yield.
- 1H NMR (CDCl3) δ 0.92-0.97 (m, 6H), 1.1 (d, 3H, J=6 Hz), 1.28 (s, 9H), 1.52-2.19 (m, 6H), 2.43 (br, 2H), 3.19 (s, 3H), 3.28-3.30 (m, 2H), 3.78 (s, 3H), 4.17-4.19 (m, 2H), 4.38 (br, 1H), 4.90-4.95 (m, 1H), 5.10 (q, 2H, J=8.7 Hz), 5.96 (m, 2H), 7.30-7.35 (m, 5H), 7.44 (d, 1H, J=7.8 Hz).
- ESI-MS (M+H+)=620
- Compound 107 was prepared in a 88% yield by reducing compound 103 with LiBH4 (1.5 eq.).
- 1H NMR (CDCl3) δ 0.92-0.99 (m, 6H), 1.26 (s, 9H), 1.66-1.73 (m, 5H), 2.21-2.50 (m, 2H), 3.20-3.32 (m, 2H), 3.62 (m, 1H), 3.75 (d, J=7.5 Hz, 2H), 4.42 (br, 1H), 4.58 (br, 1H), 5.10 (s, 2H), 7.21-7.34 (m, 4H), 7.61 (d, J=7.5 Hz, 1H).
- ESI-MS (M+H+)=563.
- Compound 108 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=612.
- Compound 109 was prepared as follows: Dry THF (5 ml) and 1-methyl-1-propenyl magnesium bromide (0.5 M in THF, 22 ml) were added to compound 106 (0.124 g, 0.2 mmol) under N2. The mixture was stirred at room temperature under N2 for 30 minutes, and then quenched by slowly adding a 10% HCl solution until the pH value was about 7. The mixture was then washed with brine and extracted with EtOAc (3×50 ml). The organic layers were combined, and dried with Na2SO4. The crude product was purified by silica gel chromatography using 2% MeOH/CH2Cl2 as an eluant to afford compound 109 as a white solid (0.085 mg, 69%).
- 1H NMR (CDCl3) δ 0.91-0.96 (m, 6H), 1.09 (d, 3H, J=6 Hz), 1.28 (s, 9H), 1.49-1.83 (m, 5H), 1.79 (s, 3H), 1.89 (d, 3H, J=6.9 Hz), 2.03-2.13 (m, 1H), 2.30-2.41 (m, 1H), 2.48 (m, 1H), 3.25-3.30 (m, 2H), 4.17-4.19 (m, 2H), 4.38-4.39 (m, 1H), 5.11 (q, 2H, J=7.8 Hz), 5.33-5.38 (m, 1H), 5.92-5.97 (m, 2H), 6.85 (q, 1H, J=6.3 Hz), 7.13-7.15 (m, 1H), 7.30-7.35 (m, 5H), 7.42 (d, 1H, J=7.8 Hz).
- ESI-MS (M+H1)=615.
- Compound 110w as prepared in a manner similar to that of compound 109 in a 44% yield.
- 1H NMR (CDCl3) δ 0.95 (m, 6H), 1.09 (d, 3H, J=6.6 Hz), 1.27 (s, 9H), 1.52-1.85 (m, 5H), 2.05-2.14 (m, 1H), 2.38-2.42 (m, 2H), 3.28-3.33 (m, 2H), 4.17-4.19 (m, 2H), 4.40-4.42 (m, 1H), 4.79-4.84 (m, 1H), 5.11 (q, 2H, J=7.8 Hz), 5.84-5.92 (m, 3H), 6.36-6.56 (m, 2H), 7.31-7.35 (m, 5H), 7.42 (d, 1H, J=7.8 Hz), 7.61 (d, 1H, J=7.2 Hz).
- ESI-MS (M+H+)=587.
- Compound III was prepared in a manner similar to that of compound 109.
- 1H NMR (CDCl3) δ 0.96 (m, 6H), 1.08 (d, 3H, J=5.7 Hz), 1.27 (s, 9H), 1.54-1.78 (m, 5H), 2.03-2.07 (m, 1H), 2.25 (s, 3H), 2.40 (m, 2H), 3.28-3.32 (m, 2H), 4.16-4.19 (m, 2H), 4.60-4.61 (m, 1H), 5.11 (q, 2H, J=6.3 Hz), 5.88 (d, 1H, J=4.8 Hz), 6.02 (s, 1H), 6.16 (d, 1H, J=16.2 Hz), 6.66 (dd, 1H, J=15.9 Hz, 5.1 Hz), 7.35 (m, 5H), 7.73 (d, 1H, J=7.5 Hz).
- ESI-MS (M+H+)=601.
- Compound 112 was prepared in a 99% yield by reacting compound 107 with SO3Py (2.5 eq.) via a Swern oxidation reaction for 1 hour.
- 1H NMR (CDCl3) δ 0.92-0.98 (m, 6H), 1.26 (s, 9H), 1.66-1.73 (m, 5H), 2.21-2.50 (m, 2H), 3.20-3.32 (m, 2H), 4.42 (br, 2H), 4.59 (br, 1H), 5.11 (s, 2H), 7.21-7.34 (m, 4H), 7.61 (d, J=7.5 Hz, 1H), 9.82 (s, 1H).
- ESI-MS (M+H+)=561.
- Compound 113 was prepared in a 68% yield in a manner similar to that of compound 89 using compound 102 as a starting material.
- 1H NMR (CDCl3) δ 0.94-0.99 (m, 6H), 1.25 (s, 9H), 1.66-1.73 (m, 5H), 2.22-2.51 (m, 4H), 3.19-3.30 (m, 2H), 4.26 (t, J=6.9 Hz, 2H), 4.44 (br, 1H), 4.57 (br, 1H), 5.12 (s, 2H), 6.82 (d, J=5.1 Hz, 1H), 7.22-7.34 (m, 4H), 7.61 (d, J=7.5 Hz, 1H).
- ESI-MS (M+H+)=657.
- Methylsulfoxide and triethylamine were added to a solution of compound 107. The solution was cooled to 0-5° C. with an ice-water bath, followed by addition of sulfur trioxide-pyridine complex. The reaction mixture was stirred at that temperature for 1 hour. After adding
- and stirring the reaction mixture at ambient temperature for another 3 hours, the reaction mixture was quenched by addition of saturated brine and subsequently extracted with ethyl acetate. The organic layers were combined, dried over MgSO4, filtered, and concentrated to afford a dark red oil. The oil was purified though a chromatography (50% EA in hexane) to afford compound 114 as a white solid.
- ESI-MS (M+H+)=627.
- Compound 115 was prepared in a manner similar to that described in Example 1 in a 65% yield.
- 1H NMR (CDCl3) δ 0.90-095 (m, 6H), 1.03-1.05 (m, 4H), 1.23 (s, 9H), 1.44-1.88 (m, 5H), 1.97 (m, 2H), 2.37 (m, 2H), 3.24-3.32 (m, 2H), 3.69 (s, 3H), 4.14 (m, 1H), 4.40-4.52 (m, 2H), 5.07 (s, 2H), 5.88-5.91 (m, 1H), 6.23 (m, 1H), 7.33 (m, 5H), 7.45 (m, 1H), 7.77 (m, 1H).
- ESI-MS (M+H+)=591.
- Compound 116 was prepared in a 77% yield in a manner similar to that of compound 109 using compound 106 as a starting material.
- 1H NMR (CDCl3) δ 0.94-0.99 (m, 6H), 1.09 (d, 3H, J=6 Hz), 1.27 (s, 9H), 1.53-1.84 (m, 5H), 2.02-2.12 (m, 1H), 2.20 (s, 3H), 2.32-2.43 (m, 2H), 3.24-3.35 (m, 2H), 5.11 (q, 2H, J=6 Hz), 5.90 (d, 1H, J=3 Hz), 5.98 (m, 1H), 7.32-7.36 (m, 5H), 7.42 (d, 1H, J=6 Hz), 7.83 (d, 1H, J=9 Hz).
- ESI-MS (M+H+)=575.
- Compound 117 was prepared by the procedures described below:
- Triethylamine (0.25 ml, 1.757 mmol, 4.53 eq.) was added to a solution of Intermediate 4 described in Example 1 (0.100 g, 0.387 mmol, 1 eq.) in DMSO (1.1 ml). The solution was cooled to 0° C. with an ice bath, followed by addition of sulfur tri oxide-pyridine complex (0.568 g, 1.742 mmol, 4.5 eq.). The ice bath was removed after the addition and the reaction mixture was stirred at room temperature for 1 hour. 1-Acetyl-3-(triphenyl-15-phosphanylidene)-pyrrolidin-2-one (0.600 g, 1.548 mmol, 4 eq.) was then added into the mixture. After stirring the mixture at room temperature overnight, the reaction was quenched by saturated brine (7 ml) and then extracted with ethyl acetate (3×10 ml). The organic layers were combined, washed with saturated brine (3×15 ml), dried over MgSO4, filtered, and concentrated to afford a dark red oil. The oil was purified through a column chromatography (2% MeOH in CH2Cl2) to afford Intermediate 9 as a white solid (75 mg, 53%). ESI-MS (M+H+)=366.
- Intermediate 9 (0.446 g, 1.220 mmol, 1 eq.) was dissolved in a solution of HCl in 1,4-dioxane (4.0 M, 10 ml) was added to. The solution was stirred at room temperature for 30 minutes and 1,4-dioxane was removed under vacuum. CH2Cl2 (1.5 ml) was then added to the residue, followed by addition of N-methylmorpholine (0.540 ml, 4.880 mmol, 4 eq.), Z-Thr(t-Bu)-Leu-OH (0.515 g, 1.220 mmol, 1.0 eq.), HOBt (0.250 g, 1.830 mmol, 1.5 eq.), and EDC (0.351 g, 1.830 mmol, 1.5 eq.). The reaction mixture was stirred at room temperature overnight and then concentrated under vacuum. The residue was partitioned between a 10% KHSO4 (6.5 ml) aqueous solution and CH2Cl2 (45 ml). The organic layer was collected, dried over MgSO4, filtered, and concentrated. The crude product was purified by flash chromatography (2% MeOH in CH2Cl2) to afford compound 117 (0.572 g, 70%) as a white solid. 1H NMR (CDCl3) δ 0.88-0.98 (m, 6H), 1.07 (d, J=6.0 Hz, 3H), 1.25 (s, 9H), 1.48-1.62 (m, 3H), 1.74-1.90 (m, 3H), 2.06-2.16 (m, 3H), 2.32-2.47 (m, 3H), 2.54 (s, 3H), 2.71 (m, 1H), 3.03 (m, 1H), 3.27-3.30 (m, 2H), 3.77 (dd, J=7.5, 7.5 Hz, 2H), 4.14-4.18 (m, 2H), 4.53 (m, 1H), 4.60 (m, 1H), 5.00-5.18 (m, 2H), 5.87 (d, J=5.1 Hz, 1H), 6.02 (br s, 1H), 6.43 (d, J=9.0 Hz, 1H), 7.27-7.34 (m, 5H), 7.76 (d, J=6.9 Hz, 1H). ESI-MS (M+H+)=670.
- Compound 118 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.9 (m, 6H), 1.16 (s, 9H), 1.49-2.17 (m, 8H), 2.38-2.41 (m, 2H) δ 3.32-3.35 (m, 2H), 3.58-3.70 (m, 2H), 4.27-4.28 (m, 1H), 4.37 (t, 3H, J=7.5 Hz), 4.57 (br, 1H), 5.10 (q, 2H, J=5.7 Hz), 6.30 (s, 1H), 6.49-6.52 (m, 2H), 6.63-6.65 (m, 1H), 7.16 (d, 1H, J=8.4 Hz), 7.34 (br, 5H), 8.17 (d, 1H, J=6.3 Hz).
- ESI-MS (M+H+)=642.
- Compound 119 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=657.
- Compound 120 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.85-0.90 (m, 6H), 1.39 (s, 9H), 1.56-1.81 (m, 5H), 2.01-2.09 (m, 4H), 2.41 (m, 1H), 3.16 (s, 3H), 3.28-3.30 (m, 2H), 3.44-3.48 (m, 2H), 3.78 (s, 3H), 4.30-4.40 (m, 2H), 4.83-4.88 (m, 1H), 5.09 (s, 2H), 5.64 (br s, 1H), 6.32 (br s, 1H), 7.26-7.33 (m, 5H), 7.77-7.79 (m, 1H).
- ESI-MS (M+H+)=645.
- Compound 121 was prepared in a manner similar to that described in Example 1 in a 10% yield.
- 1H NMR (CDCl3) δ 0.87 (m, 6H), 1.26 (s, 9H), 1.53-1.76 (m, 5H), 1.99 (m, 6H), 2.38 (m, 2H), 2.88 (m, 1H), 3.34-3.48 (m, 4H), 4.14 (m, 1H), 4.35 (m, 2H), 4.56 (m, 1H), 5.07 (s, 2H), 6.40-6.46 (m, 1H), 7.04 (m, 1H), 7.31 (m, 5H), 8.08 (m, 1H).
- ESI-MS (M+H+)=657.
- Compound 122 was prepared in a manner similar to that of compound 109 in a 60% yield.
- 1H NMR (CDCl3) δ 0.93 (m, 6H), 1.16 (s, 9H); 1.45-1.82 (m, 5H), 2.00-2.09 (m, 1H), 2.45 (s, 3H), 2.37-2.46 (m, 2H), 3.31-3.34 (m, 2H), 3.64-3.68 (m, 2H), 4.27-4.29 (m, 1H), 4.44-4.50 (m, 1H), 4.59-4.60 (m, 1H), 5.10 (q, 2H, J=5.1 Hz), 6.10 (s, 1H), 6.17 (d, 1H, J=1.2 Hz), 6.48 (br, 1H), 6.68 (dd, 2H, J=15.6 Hz, 5.7 Hz), 7.13 (d, 1H, J==8.1 Hz), 7.34 (br, 5H), 8.01 (d, 1H, J=6.9 Hz).
- ESI-MS (M+H+)=614.
- Compound 123 was prepared in a manner similar to that of compound 109 in a 32% yield.
- 1H NMR (CDCl3) δ 0.92-0.98 (m, 6H), 1.06-1.11 (m, 6H), 1.26 (s, 9H), 1.53-2.10 (m, 6H), 2.39 (m, 2H), 2.56 (q, 2H, J=7.2 Hz), 3.28-3.31 (m, 2H), 4.15-4.18 (m, 2H), 4.44-4.45 (m, 1H), 4.58 (m, 1H), 5.11 (q, 2H, J=6.3 Hz), 5.89 (d, 1H, J=4.8 Hz), 6.04 (s, 1H), 6.19 (d, 1H, J=15.3 Hz), 6.69 (dd, 1H, J=15.9 Hz, 5.4 Hz), 7.35 (m, 5H), 7.71 (d, 1H, J=7.5 Hz).
- ESI-MS (M+H+)=615.
- Compound 124 was prepared in a manner similar to that described in Example 1.
- ESI-MS (M+H+)=615.
- Compound 125 was prepared in a manner similar to that of compound 109 in a 55% yield.
- 1H NMR (CDCl3) δ 0.91 (q, 6H, J=6 Hz), 1.41 (s, 9H), 1.55-1.81 (m, 5H), 2.10 (m, 1H), 2.23 (s, 3H), 2.36-2.40 (m, 2H), 2.78 (m, 2H), 3.30-3.33 (m, 2H), 4.46-4.52 (m, 1H), 4.56-4.59 (m, 2H), 5.11 (q, 2H, J=6.6 Hz), 6.01 (d, 1H, J=8.4 Hz), 6.15 (d, 1H, J=15.6 Hz), 6.30 (s, 1H), 6.65 (dd, 1H, J=16.2 Hz, 5.4 Hz), 7.17 (d, 1H, J=8.4 Hz), 7.34 (m, 5H, 7.89 (d, 1H, J=7.8 Hz).
- ESI-MS (M+Na+)=637.
- Compound 126 was prepared in a manner similar to that of compound 109 in an 82% yield.
- 1H NMR (CDCl3) δ 0.86-0.97 (m, 6H), 1.14-1.38 (m, 6H), 1.49-1.66 (m, 1H), 1.98-2.08 (m, 2H) 2.23 (s, 3H), 2.34-2.45 (m, 2H), 3.29-3.33 (m, 2H), 3.62-3.68 (m, 2H), 4.26 (dd, J=9.9, 5.4 Hz, 1H), 4.43 (m, 1H), 4.59 (m, 1H), 5.04-5.14 (m, 2H), 6.08-6.18 (m, 2H), 6.37 (br s, 1H), 6.64-6.71 (dd, J=16.2, 5.4 Hz, 2H), 7.13 (d, J=8.4 Hz, 1H), 7.28-7.34 (m, 5H), 7.98 (d, J=6.9 Hz, 1H).
- ESI-MS (M+H+)=640.
- Compound 127 was prepared in a manner similar to that of compound 109 in a 78% yield.
- 1H NMR (CDCl3) δ 0.85-0.93 (m, 6H), 0.98 (s, 9H), 1.48-1.64 (m, 4H), 1.75-1.85 (m, 1H), 1.91 (m, 1H), 1.98-2.08 (m, 1H), 2.03 (s, 3H), 2.23 (s, 3H), 2.37-2.46 (m, 2H), 3.29-3.36 (m, 2H), 3.54-3.72 (m, 2H), 4.24 (m, 1H), 4.44 (m, 1H), 4.58 (m, 1H), 5.02-5.12 (m, 2H), 6.15 (d, J=15.9 Hz, 1H), 6.55-6.78 (m, 3H), 7.28-7.31 (m, 5H), 7.97 (d, J=6.6 Hz, 1H).
- ESI-MS (M+H+)=628.
- Compound 128 was prepared in a manner similar to that of compound 109 in a 25% yield.
- 1H NMR (CDCl3) δ 0.89 (m, 6H), 1.39 (s, 9H), 1.53-2.14 (m, 7H), 2.22 (s, 3H), 2.39 (m, 2H), 3.29-3.30 (m, 2H), 3.46 (m, 2H), 4.21 (m, 2H), 4.43 (m, 1H), 4.58 (m, 1H), 5.09 (s, 2H), 6.18 (m, 2H), 6.46 (m, 1H), 6.62-6.69 (m, 1H), 7.32 (m, 5H), 7.93 (m, 1H).
- ESI-MS (M+H+)=630.
- Compound 129 was prepared in a manner similar to that of compound 112 in a 38% yield.
- 1H NMR (CDCl3) δ 0.92-0.98 (m, 6H), 1.27 (s, 9H), 1.65-1.72 (m, 5H), 2.22-2.51 (m, 2H), 3.20-3.32 (m, 2H), 4.43 (br, 2H), 4.59 (br, 1H), 5.12 (s, 2H), 7.21-7.35 (m, 4H), 7.60 (d, J=7.5 Hz, 1H), 9.82 (s, 1H)
- ESI-MS (M+H+)=604.3.
- Compound 130 was prepared in a manner similar to that of compound 131.
- 1H NMR (CDCl3) δ 0.93-0.98 (m, 6H), 1.26 (s, 9H), 1.65-1.72 (m, 5H), 2.22-2.51 (m, 2H), 3.20-3.32 (m, 2H), 3.58 (d, J=7.2 Hz, 2H), 3.86 (m, 1H), 4.44 (br, 2H), 5.12 (s, 2H), 7.21-7.35 (m, 4H), 7.60 (d, J=7.5 Hz, 1H).
- ESI-MS (M+H+)=624.3.
- Compound 131 was prepared in a 51% yield by reacting compound 107 with thionyl chloride in CH2Cl2 at room temperature for 6 hours.
- 1H NMR (CDCl3) δ 0.93-0.98 (m, 6H), 128 (s, 9H), 1.65-1.72 (m, 5H), 2.22-2.50 (m, 2H), 3.20-3.32 (m, 2H), 3.58 (d, J=7.2 Hz, 2H), 3.86 (m, 1H), 4.42 (br, 2H), 5.11 (s, 2H), 7.21-7.35 (m, 4H), 7.60 (d, J=7.5 Hz, 1H).
- ESI-MS (M+H+)=581.3.
- 1-(2,2,2-Trifluoro-1-methyl-ethylidene)-pyrrolidinium (1.5 eq.) was prepared from methyltrifluoromethylketone and pyrrolidine at 0° C. Compound 112 (1.0 eq.) was then added in situ to afford compound 132 in a 43% yield.
- 1H NMR (CDCl3) δ 0.94-0.98 (m, 6H), 1.27 (s, 9H), 1.66-1.73 (m, 5H), 2.25-2.53 (m, 2H), 3.22-3.31 (m, 2H), 4.44 (m, 1H), 4.63 (m, 1H), 5.10 (s, 2H), 6.21 (d, J=18.1 Hz, 1H), 6.98 (dd, J=18.1 Hz, 5.1 Hz, 1H), 7.22-7.35 (m, 4H), 7.62 (d, J=7.5 Hz, 1H).
- ESI-MS (M+H+)=655.
- Compound 133 was prepared in a manner similar to that of compound 112 in a 35% yield.
- 1H NMR (CDCl3) δ 0.89-0.95 (m, 6H), 1.42 (s, 9H), 1.55-2.06 (m, 6H) 2.37-2.47 (m, 2H), 2.64-2.94 (m, 2H), 3.32-3.34 (m, 2H), 4.45-4.58 (m, 3H), 5.12 (s, 2H), 6.00-6.16 (m, 2H), 7.35 (m, 5H), 9.49 (d, 1H, J=16.5 Hz).
- ESI-MS (M+H1)=575.
- Compound 134 was prepared in a manner similar to that of compound 112 in a 35% yield.
- 1H NMR (CDCl3) δ 0.87-1.26 (m, 20H), 1.69-1.97 (m, 14H), 2.43 (m, 1H), 3.64 (m, 1H), 4.18 (m, 2H), 4.40 (m, 1H), 5.09 (s, 2H), 5.90 (m, 1H), 7.36 (m, 5H), 9.50 (s, 1H).
- ESI-MS (M+H+)=601.
- Compound 135 was prepared in a manner similar to that of compound 109.
- 1H NMR (CDCl3) δ 0.93 (q, 6H, J=5.7 Hz), 1.03-1.08 (m, 9H), 1.23 (s, 9H), 1.49-1.83 (m, 5H), 2.00-2.03 (m, 1H), 2.36 (m, 2H), 2.70-2.79 (m, 1H), 3.26-3.29 (m, 2H), 4.13-4.17 (m, 2H), 4.43-4.44 (m, 1H), 4.58-4.60 (m, 1H), 5.09 (q, 2H, J=5.4 Hz), 5.86 (d, 1H, J=5.1 Hz), 6.01 (s, 1H), 6.26 (d, 1H, J=15.6 Hz), 6.71 (dd, 1H, J=15.6 Hz, 5.4 Hz), 7.30-7.34 (m, 5H), 7.60 (d, 1H, J=7.8 Hz).
- ESI-MS (M+H+)=629.
- Compound 136 was prepared in a manner similar to that of compound 109 in a 36% yield.
- 1H NMR (CDCl3) δ 0.93 (q, 6H, J=5.7 Hz), 1.06 (d, 3H, J=6.3 Hz), 1.23 (s, 9H), 1.44-1.77 (m, 5H), 1.99-2.07 (m, 1H), 2.39 (m, 2H), 3.27-3.30 (m, 2H), 4.15-4.18 (m, 2H), 4.39-4.41 (m, 1H), 4.62 (m, 1H), 5.10 (q, 2H, J=6 Hz), 5.82-5.87 (m, 3H), 6.28 (d, 1H, J=16.5 Hz). 6.47-6.56 (m, 2H), 6.77 (dd, 1H, J=15.3 Hz, 4.8 Hz), 7.29-7.34 (m, 5H), 7.66 (d, 1H, J=7.5 Hz).
- ESI-MS (M+Na+)=635.
- Compound 137 was prepared in a manner similar to that of compound 109.
- 1H NMR (CDCl3) δ 0.94-0.97 (m, 6H), 1.08 (d, 3H, J=6.3 Hz), 1.27 (s, 9H), 1.52-1.86 (m, 11H), 2.02-2.09 (m, 1H), 2.40 (m, 2H), 3.29-3.32 (m, 2H), 4.16 (m, 2H), 4.41 (m, 1H), 4.62 (m, 1H), 5.11 (q, 2H, J=5.4 Hz), 5.81-5.89 (m, 2H), 6.61-6.79 (m, 3H), 7.35 (m, 5H), 7.53 (d, 1H, J=7.2 Hz).
- ESI-MS (M+H+)=641.
- Compound 138 was prepared in a manner similar to that of compound 109 in a 26% yield.
- 1H NMR (CDCl3) δ 0.87-1.26 (m, 20H), 1.52-1.72 (m, 9H), 2.21-2.22 (m, 3H), 2.38 (m, 2H), 3.27-3.30 (m, 2H), 4.15 (m, 2H), 4.39 (m, 1H), 4.58 (m, 1H), 5.09 (s, 2H), 5.86 (m, 2H), 6.12-6.22 (m, 1H), 6.61-6.68 (m, 1H), 7.33 (m, 5H), 7.65 (m, 1H).
- ESI-MS (M+H+)=641.
- Compound 139 was prepared in a manner similar to that of compound 109 in a 28% yield.
- 1H NMR (CDCl3) δ 0.62-0.70 (m, 8H), 0.79-0.80 (m, 6H), 0.99 (s, 9H), 1.26-1.85 (m, 6H), 2.12 (m, 2H), 3.00-3.03 (m, 2H), 4.16 (m, 2H), 4.46 (m, 1H), 4.62 (m, 1H), 5.06-5.16 (m, 2H), 5.89 (s, 1H), 6.10 (s, 1H), 6.32 (d, 1H, J=15.6 Hz), 6.74 (dd, 1H, J=15.6 Hz, 5.1 Hz), 7.36 (m, 5H), 7.69 (m, 1H).
- ESI-MS (M+Na+)=649.
- Compound 140 was prepared in a manner similar to that of compound 109 in a 37% yield.
- 1H NMR (CDCl3) δ 0.93 (q, 6H, J=6 Hz), 1.04 (d, 3H, J=6 Hz), 1.23 (s, 9H), 1.49-1.83 (m, 5H), 1.89 (s, 3H), 1.99-2.09 (m, 1H), 2.37-2.42 (m, 2H), 3.27 (d, 2H, J=9 Hz), 4.12-4.17 (m, 2H), 4.39-4.44 (m, 1H), 4.58-4.63 (m, 1H), 5.09 (q, 2H, J=5.4 Hz), 5.78 (s, 1H), 5.86 (d, 1H, J=5.1 Hz), 5.94 (s, 1H), 6.00 (m, 2H), 6.72-6.74 (m, 2H), 7.30-7.34 (m, 5H), 7.63 (d, 1H, J=7.5 Hz).
- ESI-MS (M+H+)=627.
- Compound 141 was prepared in a manner similar to that of compound 109 in a 82% yield.
- 1H NMR (CDCl3) δ 0.86-1.02 (m, 15H), 1.09-1.31 (m, 9H), 1.45-1.85 (m, 6H), 2.16-2.24 (m, 2H), 2.22 (s, 3H), 2.30-2.41 (m, 2H), 3.22-3.32 (m, 2H), 4.10 (dd, J=5.4, 5.4 Hz, 1H), 4.23 (ddd, J=8.1, 6.0, 2.4 Hz, 1H), 4.46 (m, 1H), 4.63 (m, 1H), 4.99-5.14 (m, 2H), 5.38 (d, J=5.1 Hz, 1H), 5.88 (br s, 1H), 6.69 (dd, J=15.9, 5.1 Hz, 1H), 7.14 (d, J=6.0 Hz, 1H), 7.32-7.37 (m, 5H), 7.43 (m, 1H).
- ESI-MS (M+H+)=700.
- Compound 142 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.73-0.87 (m, 5H), 1.03 (d, J=6.0 Hz, 3H), 1.05 (d, J=6.0 Hz, 3H), 1.14 (s, 3H), 1.22-1.28 (m, 18H), 1.77-1.82 (m, 1H), 2.04-2.12 (m, 1H), 2.32-2.48 (m, 2H), 3.28-3.32 (m, 2H), 4.13-4.19 (m, 6H), 4.32-4.35 (m, 1H), 4.69-4.78 (m, 1H), 5.05-5.16 (m, 2H), 5.50 (br s, 1H), 5.89 (d, J=18, 1H), 6.13 (d, J=16 Hz, 1H), 6.85 (dd, J=16.0, 5.5 Hz, 1H), 7.08 (d, J=9.0 Hz, 1H), 7.34 (m, 5H), 7.63 (d, J=6.0 Hz, 1H).
- ESI-MS (M+Na+)=675.
- Compound 143 was prepared in a manner similar to that of compound 109 in a 82% yield.
- 1H NMR (CDCl3) δ 0.84-0.94 (m, 6H), 1.10 (d, J=6.0 Hz, 3H), 1.15-1.24 (m, 5H), 1.49-1.79 (m, 10H), 2.03 (m, 1H), 2.22 (s, 3H), 2.38 (m, 2H), 3.28-3.31 (m, 2H), 3.39 (m, 1H), 4.15 (m, 2H), 4.45-4.58 (m, 2H), 5.09 (s, 2H), 5.75 (d, J=5.7 Hz, 1H), 5.90 (br s, 1H), 6.15 (d, J=15.9 Hz, 1H), 6.65 (dd, J=15.9, 5.4 Hz, 1H), 7.12 (d, J=7.8 Hz, 1H), 7.30-7.34 (m, 5H), 7.75 (d, J=7.5 Hz, 1H).
- ESI-MS (M+H+)=627.
- Compound 144 was prepared in a manner similar to that described in Example 1.
- 1H NMR (CDCl3) δ 0.86-1.27 (m, 17H), 1.47-1.76 (m, 14H), 1.97-2.05 (m, 1H), 2.38 (br s, 2H), 3.28 (m, 2H), 4.15 (m, 4H), 4.38 (m, 1H), 4.58 (m, 1H), 5.04-5.14 (m, 2H), 5.79-5.93 (m, 3H), 6.80 (dd, 1H, J=15.9 Hz, 5.7 Hz), 7.34 (m, 5H), 7.60 (m, 1H).
- ESI-MS (M+H+)=671.
- Compound 145 was prepared in a manner similar to that of compound 109 in a 25% yield.
- 1H NMR (CDCl3) δ 0.73-0.87 (m, 5H), 0.95 (d, J=6.0 Hz, 3H), 1.14 (s, 9H), 1.47-1.69 (m, 13H), 1.90-1.99 (m, 3H), 2.00-2.36 (m, 3H), 3.17 (m, 2H), 4.05 (m, 2H), 4.30 (m, 1H), 4.51 (m, 1H), 4.94-5.04 (m, 2H), 5.77-5.81 (m, 2H), 6.21 (d, J=16.0 Hz 1H), 6.62 (dd, J=16.0, 5.5 Hz, 1H), 7.34 (m, 5H), 7.52 (d, J=7.8 Hz, 1H).
- ESI-MS (M+Na+)=667.
- A fusion protein, prepared by fusing a severe acute respiratory syndrome 3CL protease to E. coli maltose-binding protein (MBP), was expressed in E coli BL21 (DE3) pLys S cells (Novagen, Oakland, Calif.). Fusion protein thus obtained was purified by amylose-affinity chromatography and cleaved with factor Xa to release the severe acute respiratory syndrome 3CL protease. Subsequently, the recombinant protease was purified to homogeneity using phenyl Sepharose CL-4B column (Pharmacia, Uppsala, Sweden) and was concentrated to form a 25 μM solution.
- The enzymatic activity of severe acute respiratory syndrome 3CL protease (75 nM) was determined by incubation with a solution containing 15 μM of a substrate peptide (SITSAVLQSGFRKMA, SEQ ID No: 1) at 25° C. for 30 minutes in a medium containing 20 mM Tris-HCl (pH 7.5), 200 mM NaCl, 1 mM EDTA, 1 mM dithiothretol, and 1 mg/mL bovine serum albumin. The reaction was terminated by adding an equal volume of 0.2% trifluoroacetic acid. The reaction mixture was analyzed by reverse-phase HPLC using a C18 column. Cleaved products were resolved using a 5-95% linear gradient of acetonitrile in 0.9% trifluoroacetic acid. Quantification of peak areas was used to determine the extent of substrate conversion.
- Compounds 1-145 were tested for their efficacy in inhibiting severe acute respiratory syndrome 3CL protease. Specifically, a test compound and the severe acute respiratory syndrome 3CL protease were pre-incubated at 25° C. for 20 minutes before they were incubated with the substrate peptide. Unexpectedly, 77 compounds show IC50 values lower than 1 μM, 32 compounds show IC50 values between 1 μM and 10 μM, and 12 compounds show IC50 values above 10 μM.
- All of the features disclosed in this specification may be combined in any combination. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.
- From the above description, one skilled in the art can easily ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, other embodiments are also within the scope of the following claims.
Claims (24)
1. A method for treating an infection with a virus, comprising administering to a subject in need thereof an effective amount of a compound of the formula (I); wherein
X is N(Ra1), O, or CH2; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; in which Ra1 is H or C1-C15 alkyl;
R1 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, C(O)Rb1, CO2Rb1, C(O)NRb1Rb2, C(O)—N(Rb1)—ORb2, C(S)Rb1, C(S)NRb1Rb2, S(O)Rb1, SO2Rb1, S(O)NRb1Rb2, S(O)—N(Rb1)—ORb2, SO2NRb1Rb2, or SO3Rb1; in which each of Rb1 and Rb2, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl;
each of R2 and R3, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, ORc1, SRc1, or NRc1Rc2; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; in which each of Rc1 and Rc2, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl;
each of R4 and R5, independently, is H, halogen, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl;
one of R6 and R7 is C1-C15 alkyl substituted with C3-C20 heterocycloalkyl, heteroaryl, or aryl; and the other of R6 and R7 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl;
R8 is H, halogen, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, ORd1, or SRd1; in which Rd1 is H and C1-C15 alkyl; and
each of R9 and R10, independently, is H, halogen, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, C(O)Re1, CO2Re1, C(O)NRe1Re2, C(O)—N(Re1)—ORe2, C(S)Re1, C(S)NRe1Re2, CN, NO2, S(O)Re1, SO2Re1, S(O)NRe1Re2, S(O)—N(Re1)—ORe2, SO2NRe1Re2, SO3Re1, PO(ORe1)(ORe2), PO(Re1)(Re2), PO(NRe1Re2)(ORe3), PO(NR e1Re2)(NRe3Re4), C(O)—N(Re1)—NRe2Re3, or C(S)—N(Re1)—NRe2Re3; or R8 and R10, taken together, are C3-C20 cycloalkyl or C3-C20 heterocycloalkyl; or R9 and R10, taken together, are C3-C20 cycloalkyl or C3-C20 heterocycloalkyl; in which each of Re1, Re2, Re3, and Re4, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl; or any two of Re1, Re2, Re3, and Re4, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; and
the virus is a coronavirus or a hepatitis C virus.
2. The method of claim 1 , wherein X is N(Ra1) or O; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; R1 is H, C(O)Rb1, CO2Rb1, C(O)NRb1Rb2, C(S)NRb1Rb2, or SO2Rb1; each of R2 and R3, independently, is H or C1-C15 alkyl; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; each of R4 and R5, independently, is H or C1-C15 alkyl; one of R6 and R7 is C1-C15 alkyl substituted with C3-C20 heterocycloalkyl, and the other of R6 and R7 is H; R8 is H; and each of R9 and R10, independently, is H or CO2Rc1.
4. The method of claim 3 , wherein one of R2 and R3 is H or C1-C15 alkyl optionally substituted with halogen, heteroaryl, aryl, ORc1, SRc1, OC(O)Rc1, CO2Rc1, C(O)NRc1Rc2, NRc1Rc2, N(Rc1)—CO2Rc2, N(Rc1)—C(O)Rc2, N(Rc1)—C(O)—NRc2Rc3, N(Rc1)—SO2Rc2, SO2Rc1, or O—SO2—Rc1; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; in which Rc3 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl.
5. The method of claim 4 , wherein one of R4 and R5 is H or C1-C15 alkyl optionally substituted with halogen, aryl, ORf1, SRf1, CO2Rf1, C(O)NRf1Rf2, SO2Rf1, SO3Rf1, or NRf1Rf2; in which each of Rf1 and Rf2, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl.
6. The method of claim 1 , wherein the coronavirus is a severe acute respiratory syndrome virus or a human coronavirus 229E.
7. The method of claim 1 , wherein the virus is a hepatitis C virus.
8. A method for inhibiting a viral protease, comprising contacting the protease with an effective amount of a compound of the formula (I): wherein
X is N(Ra1), O, or CH2; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; in which Ra1 is H or C1-C15 alkyl;
R1 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, C(O)Rb1, CO2Rb1, C(O)NRb1Rb2, C(O)—N(Rb1)—ORb2, C(S)Rb1, C(S)NRb1Rb2, S(O)Rb1, SO2Rb1, S(O)NRb1Rb2, S(O)—N(Rb1)—ORb2, SO2NRb1Rb2, or SO3Rb1; in which each of Rb1 and Rb2, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl;
each of R2 and R3, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, ORc1, SRc1, or NRc1Rc2; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; in which each of Rc1 and Rc2, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl;
each of R4 and R5, independently, is H, halogen, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl;
one of R6 and R7 is C1-C15 alkyl substituted with C3-C20 heterocycloalkyl, heteroaryl, or aryl; and the other of R6 and R7 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl;
R8 is H, halogen, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, ORd1, or SRd1; in which Rd1 is H and C1-C15 alkyl; and
each of R9 and R10, independently, is H, halogen, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, aryl, C(O)Re1, CO2Re1, C(O)NRe1Re2, C(O)—N(Re1)—ORe2, C(S)Re1, C(S)NRe1Re2, CN, NO2, S(O)Re1, SO2Re1, S(O)NRe1Re2, S(O)—N(Re1)—ORe2, SO2NRe1Re2, SO3Re1, PO(ORe1)(ORe2), PO(Re1)(Re2), PO(NRe1Re2)(ORe3), PO(NRe1Re2)(NRe3Re4), C(O)—N(Re1)—NRe2Re3, or C(S)—N(Re1)—NRe2Re3; or R8 and R10, taken together, are C3-C20 cycloalkyl or C3-C20 heterocycloalkyl; or R9 and R10, taken together, are C3-C20 cycloalkyl or C3-C20 heterocycloalkyl; in which each of Re1, Re2, Re3, and Re4, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl; or any two of Re1, Re2, Re3, and Re4, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; and
the viral protease is a coronaviral 3CL protease or a hepatitis C viral protease.
9. The method of claim 8 , wherein X is N(Ra1) or O; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; R1 is H, C(O)Rb1, CO2Rb1, C(O)NRb1Rb2, C(S)NRb1Rb2, or SO2Rb1; each of R2 and R3, independently, is H or C1-C15 alkyl; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; each of R4 and R5, independently, is H or C1-C15 alkyl; one of R6 and R7 is C1-C15 alkyl substituted with C3-C20 heterocycloalkyl, and the other of R6 and R7 is H; R8 is H; and each of R9 and R10, independently, is H or CO2Rc1.
11. The method of claim 10 , wherein one of R2 and R3 is H or C1-C15 alkyl optionally substituted with halogen, heteroaryl, aryl, ORc1, SRc1, OC(O)Rc1, CO2Rc1, C(O)NRc1Rc2, NRc1Rc2, N(Rc1)—CO2Rc2, N(Rc1)—C(O)Rc2, N(Rc1)—C(O)—NRc2Rc3, N(Rc1)—SO2Rc2, SO2Rc1, or O—SO2—Rc1; or X and one of R2 and R3, together with the atom or atoms to which they are bonded, are C3-C20 heterocycloalkyl; in which Rc3 is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl.
12. The method of claim 11 , wherein one of R4 and R5 is H or C1-C15 alkyl optionally substituted with halogen, aryl, ORf1, SRf1, CO2Rf1, C(O)NRf1Rf2, SO2Rf1, SO3Rf1, or NRf1Rf2; in which each of Rf1 and Rf2, independently, is H, C1-C15 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, heteroaryl, or aryl.
13. The method of claim 8 , wherein the coronaviral 3CL protease is a severe acute respiratory syndrome viral 3CL protease or a human coronaviral 229E protease.
14. The method of claim 8 , wherein the viral protease is a hepatitis C viral protease.
15. The method of claim 1 , wherein the compound is one of compounds 5, 6, 8, 59, 89, 99, 102, 103, 105, 111, 112, 113, 114, 123, 124, 125, 128, 129, 133, 139, 141, and 143.
16. The method of claim. 8, wherein the compound is one of compounds 5, 6, 8, 59, 89, 99, 102, 103, 105, 111, 112, 113, 114, 123, 124, 125, 128, 129, 133, 139, 141, and 143.
17. The method of claim 1 , wherein the virus is a coronavirus.
18. The method of claim 8 , wherein the viral protease is a coronaviral 3CL protease.
19. The method of claim 17 , wherein the compound is one of compounds 5, 6, 8, 59, 89, 99, 102, 103, 105, 111, 112, 113, 114, 123, 124, 125, 128, 129, 133, 139, 141, and 143.
20. The method of claim 18 , wherein the compound is one of compounds 5, 6, 8, 59, 89, 99, 102, 103, 105, 111, 112, 113, 114, 123, 124, 125, 128, 129, 133, 139, 141, and 143.
21. The method of claim 1 , wherein the compound, is one of compounds 5, 6, 59, 102, 103, 105, 111, 112, 113, 114, 124, and 125.
22. The method of claim 8 , wherein the compound is one of compounds 5, 6, 59, 102, 103, 105, 111, 112, 113, 114, 124, and 125.
23. The method of claim 17 , wherein the compound is one of compounds 5, 6, 59, 102, 103, 105, 111, 112, 113, 114, 124, and 125.
24. The method of claim 18 , wherein the compound is one of compounds 5, 6, 59, 102, 103, 105, 111, 112, 113, 114, 124, and 125.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/949,364 US20080125375A1 (en) | 2003-12-31 | 2007-12-03 | Protease inhibitors |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53377903P | 2003-12-31 | 2003-12-31 | |
US11/024,929 US7304088B2 (en) | 2003-12-31 | 2004-12-29 | Protease inhibitors |
US11/949,364 US20080125375A1 (en) | 2003-12-31 | 2007-12-03 | Protease inhibitors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/024,929 Division US7304088B2 (en) | 2003-12-31 | 2004-12-29 | Protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080125375A1 true US20080125375A1 (en) | 2008-05-29 |
Family
ID=34748959
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/024,929 Expired - Fee Related US7304088B2 (en) | 2003-12-31 | 2004-12-29 | Protease inhibitors |
US11/949,364 Abandoned US20080125375A1 (en) | 2003-12-31 | 2007-12-03 | Protease inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/024,929 Expired - Fee Related US7304088B2 (en) | 2003-12-31 | 2004-12-29 | Protease inhibitors |
Country Status (7)
Country | Link |
---|---|
US (2) | US7304088B2 (en) |
EP (1) | EP1704142A4 (en) |
CN (1) | CN1922137A (en) |
AU (1) | AU2004312547A1 (en) |
CA (1) | CA2550515A1 (en) |
TW (1) | TW200524578A (en) |
WO (1) | WO2005066123A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100160368A1 (en) * | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
US20110207766A1 (en) * | 2009-07-13 | 2011-08-25 | Graceway Pharmaceuticals, Llc. | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
US10238644B2 (en) | 2008-12-19 | 2019-03-26 | Medicis Pharmaceutical Corporation | 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100363346C (en) * | 2004-10-22 | 2008-01-23 | 清华大学 | Small molecular inhibiting agent for coronavirus main proteinase, its preparation method and uses |
UY32827A (en) * | 2009-08-12 | 2011-02-28 | Glaxo Group Ltd | CATEPSIN C INHIBITORS |
CN102838523A (en) * | 2011-06-23 | 2012-12-26 | 南开大学 | Anti-enterovirus 71 (EV71) valerolactam compounds, preparation method and uses thereof |
CA3024120A1 (en) * | 2016-05-13 | 2017-11-16 | Emory University | Peptidomimetics for the treatment of norovirus infection |
CN114026067A (en) * | 2019-06-05 | 2022-02-08 | 埃默里大学 | Peptide mimetics for the treatment of coronavirus and picornavirus infections |
US11124497B1 (en) | 2020-04-17 | 2021-09-21 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
US11174231B1 (en) | 2020-06-09 | 2021-11-16 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
WO2022020711A1 (en) * | 2020-07-24 | 2022-01-27 | The Texas A&M University System | Sars-cov-2 main protease inhibitors |
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
WO2022156693A1 (en) * | 2021-01-19 | 2022-07-28 | 中国人民解放军军事科学院军事医学研究院 | Viral protease inhibitor containing n-(substituted sulfonyl) acetamide structure and application thereof in antiviral drugs |
CN115322130A (en) * | 2022-08-02 | 2022-11-11 | 南京正济医药研究有限公司 | Preparation of (S) -2- (BOC-amino) -3- [ (S) -2-oxo-3-pyrrolidinyl ] propionic acid methyl ester |
CN115650881A (en) * | 2022-09-06 | 2023-01-31 | 浙江医药股份有限公司新昌制药厂 | Process method for synthesizing quinolone compound intermediate by using microreactor |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5692487A (en) * | 1995-05-03 | 1997-12-02 | Siemens Aktiengesellschaft | Method for parametrizing a linear lambda controller for an internal combustion engine |
US5856530A (en) * | 1996-05-14 | 1999-01-05 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and methods for their use and preparation |
US6214799B1 (en) * | 1996-05-14 | 2001-04-10 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and methods for their use and preparation |
US20010047006A1 (en) * | 1999-12-03 | 2001-11-29 | Dragovich Peter S. | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
US20020006943A1 (en) * | 2000-04-14 | 2002-01-17 | Johnson , Jr. Theodore O. | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
US6355807B1 (en) * | 1999-08-24 | 2002-03-12 | Agouron Pharmaceuticals, Inc. | Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates |
US20020133020A1 (en) * | 1999-08-24 | 2002-09-19 | Agouron Pharmaceuticals, Inc. | Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates |
US6531452B1 (en) * | 1998-04-30 | 2003-03-11 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
US6534530B1 (en) * | 1999-08-04 | 2003-03-18 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
US20060014821A1 (en) * | 2003-08-27 | 2006-01-19 | Agouron Pharmaceuticals, Inc. | Inhibitors of SARS 3C like protease |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2254343A1 (en) * | 1996-05-14 | 1997-11-20 | Agouron Pharmaceuticals, Inc. | Inhibitors of picornavirus 3c proteases and methods for their use and preparation |
US5962487A (en) * | 1997-12-16 | 1999-10-05 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and methods for their use and preparation |
WO2004093860A1 (en) * | 2003-04-21 | 2004-11-04 | Pfizer Inc. | Inhibitors of sars related coronavirus proteinase |
-
2004
- 2004-12-28 CN CNA2004800393984A patent/CN1922137A/en active Pending
- 2004-12-28 EP EP04815989A patent/EP1704142A4/en not_active Withdrawn
- 2004-12-28 AU AU2004312547A patent/AU2004312547A1/en not_active Abandoned
- 2004-12-28 CA CA002550515A patent/CA2550515A1/en not_active Abandoned
- 2004-12-28 WO PCT/US2004/044004 patent/WO2005066123A1/en active Application Filing
- 2004-12-29 TW TW093141198A patent/TW200524578A/en unknown
- 2004-12-29 US US11/024,929 patent/US7304088B2/en not_active Expired - Fee Related
-
2007
- 2007-12-03 US US11/949,364 patent/US20080125375A1/en not_active Abandoned
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5692487A (en) * | 1995-05-03 | 1997-12-02 | Siemens Aktiengesellschaft | Method for parametrizing a linear lambda controller for an internal combustion engine |
US5856530A (en) * | 1996-05-14 | 1999-01-05 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and methods for their use and preparation |
US6214799B1 (en) * | 1996-05-14 | 2001-04-10 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and methods for their use and preparation |
US6362166B1 (en) * | 1996-05-14 | 2002-03-26 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and methods for their use and preparation |
US6531452B1 (en) * | 1998-04-30 | 2003-03-11 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
US6534530B1 (en) * | 1999-08-04 | 2003-03-18 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
US6355807B1 (en) * | 1999-08-24 | 2002-03-12 | Agouron Pharmaceuticals, Inc. | Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates |
US20020133020A1 (en) * | 1999-08-24 | 2002-09-19 | Agouron Pharmaceuticals, Inc. | Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates |
US20010047006A1 (en) * | 1999-12-03 | 2001-11-29 | Dragovich Peter S. | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
US6514997B2 (en) * | 1999-12-03 | 2003-02-04 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
US20020006943A1 (en) * | 2000-04-14 | 2002-01-17 | Johnson , Jr. Theodore O. | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
US20060014821A1 (en) * | 2003-08-27 | 2006-01-19 | Agouron Pharmaceuticals, Inc. | Inhibitors of SARS 3C like protease |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100160368A1 (en) * | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
US8598196B2 (en) | 2008-08-18 | 2013-12-03 | Medicis Pharmaceutical Corporation | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
US9271973B2 (en) | 2008-08-18 | 2016-03-01 | Medicis Pharmaceutical Corporation | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
US10238644B2 (en) | 2008-12-19 | 2019-03-26 | Medicis Pharmaceutical Corporation | 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
US11318130B2 (en) | 2008-12-19 | 2022-05-03 | Medicis Pharmaceutical Corporation | 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
US20110207766A1 (en) * | 2009-07-13 | 2011-08-25 | Graceway Pharmaceuticals, Llc. | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
US8642616B2 (en) | 2009-07-13 | 2014-02-04 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
US9078889B2 (en) | 2009-07-13 | 2015-07-14 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
US9980955B2 (en) | 2009-07-13 | 2018-05-29 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
US10238645B2 (en) | 2009-07-13 | 2019-03-26 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
US10918635B2 (en) | 2009-07-13 | 2021-02-16 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
US11850245B2 (en) | 2009-07-13 | 2023-12-26 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
Also Published As
Publication number | Publication date |
---|---|
US20050143319A1 (en) | 2005-06-30 |
AU2004312547A1 (en) | 2005-07-21 |
US7304088B2 (en) | 2007-12-04 |
WO2005066123A1 (en) | 2005-07-21 |
CA2550515A1 (en) | 2005-07-21 |
TW200524578A (en) | 2005-08-01 |
EP1704142A4 (en) | 2008-08-20 |
CN1922137A (en) | 2007-02-28 |
EP1704142A1 (en) | 2006-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7462594B2 (en) | Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases | |
US20080125375A1 (en) | Protease inhibitors | |
DE69531990T2 (en) | BICYCLIC LACTAMINE HIBITOR OF THE INTERLEUKIN-1-BETA-CONVERTING ENZYME | |
EP0184550B1 (en) | 5-amino-4-hydroxy valeryl amide derivatives | |
WO2022020711A1 (en) | Sars-cov-2 main protease inhibitors | |
KR100611540B1 (en) | Dolastatin 10 derivatives | |
US5962487A (en) | Antipicornaviral compounds and methods for their use and preparation | |
EA029672B1 (en) | Method of treating contrast-induced nephropathy | |
FR2518088A1 (en) | NOVEL AMINOACID DERIVATIVES AND THEIR THERAPEUTIC APPLICATION | |
EA019749B1 (en) | Antiviral compounds | |
JPH07179414A (en) | Urethanes and ureas which induce formation of cytokine | |
NZ260675A (en) | Phosphinyloxymethyl ketones containing 1-3 amino acids as enzyme inhibitors; medicaments | |
JP4417551B2 (en) | Hemia Stalin analog | |
US6255286B1 (en) | Depsipeptides and drugs containing the same as the active ingredient | |
CN114591201A (en) | Beta-elemene derivative with HDACI pharmacophore and preparation method and application thereof | |
AU8660491A (en) | N-(2-alkyl-3-mercaptoglutaryl)-amino-diaza cycloalkanone derivatives and their use as collagenase inhibitors | |
CA2021944A1 (en) | Antiherpetic agents | |
GB2171698A (en) | Ester substituted aminoalkanoylureido amino and imino acid and ester compounds | |
ES2206907T3 (en) | ANTI-PICORNAVIRUS COMPOUNDS, COMPOSITIONS CONTAINING THESE COMPOUNDS AND THEIR USE PROCEDURES. | |
RU2181123C2 (en) | Pharmaceutical composition with fungicide activity and derivatives of dipeptide of alpha-amino acid or its derivative and cyclopentane-beta-amino acid or its derivative | |
WO1999031052A1 (en) | Novel metalloproteinase inhibitors | |
JPH08501067A (en) | Peptide compounds | |
MXPA00005677A (en) | Hemiasterlin analogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TAIGEN BIOTECHNOLOGY, TAIWAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YANG, SYAULAN;WU, JEN-DAR;SU, FENG-YIH;AND OTHERS;REEL/FRAME:020192/0145 Effective date: 20041224 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |